Sections

Guidelines

Guidelines Summary

ADA guidelines on managing hypertension

Guidelines published in 2017 by the American Diabetes Association (ADA) on managing hypertension in patients with diabetes state the following^{[400, 401]}:

Blood pressure should be measured at every routine clinical care visit; patients found to have an elevated blood pressure (≥140/90 mm Hg) should have blood pressure confirmed using multiple readings, including measurements on a separate day, to diagnose hypertension; in the ADA’s Standards of Care in Diabetes—2023, hypertension was redefined as a blood pressure ≥130/80 mm Hg ^{[351, 352]}
All hypertensive patients with diabetes should have home blood pressure monitored to identify white-coat hypertension
Orthostatic measurement of blood pressure should be performed during initial evaluation of hypertension and periodically at follow-up, or when symptoms of orthostatic hypotension are present, and regularly if orthostatic hypotension has been diagnosed
These guidelines state that most patients with diabetes and hypertension should be treated to a systolic blood pressure goal of < 140 mm Hg and a diastolic blood pressure goal of < 90 mm Hg; however, in the ADA’s Standards of Care in Diabetes—2023, it was advised that the target blood pressure for people with diabetes be below 130/80 mm Hg, if it can be safely achieved ^{[351, 352]}
For patients with systolic blood pressure >120 mm Hg or diastolic blood pressure >80 mm Hg, lifestyle intervention consists of weight loss if the patients are overweight or obese; a Dietary Approaches to Stop Hypertension (DASH)–style dietary pattern, including reduced sodium and increased potassium intake, increased fruit and vegetable consumption, moderation of alcohol intake, and increased physical activity
Patients with confirmed office-based blood pressure ≥160/100 mm Hg should, in addition to lifestyle therapy, have prompt initiation and timely titration of two drugs or a single-pill combination of drugs demonstrated to reduce cardiovascular events in patients with diabetes
Treatment for hypertension should include drug classes demonstrated to reduce cardiovascular events in patients with diabetes: angiotensin-converting enzyme (ACE) inhibitors, angiotensin-receptor blockers (ARBs), thiazide-like diuretics, or dihydropyridine calcium channel blockers; multiple-drug therapy is generally required to achieve blood pressure targets (but not a combination of ACE inhibitors and ARBs)
An ACE inhibitor or ARB, at the maximum tolerated dose indicated for blood pressure treatment, is the recommended first-line treatment for hypertension in patients with diabetes and a urine albumin-to-creatinine ratio of ≥300 mg/g creatinine or 30–299 mg/g creatinine; if one class is not tolerated, the other should be substituted
For patients treated with an ACE inhibitor, ARB, or diuretic, serum creatinine/estimated glomerular filtration rate and serum potassium levels should be monitored
Pregnant women with diabetes and preexisting hypertension or mild gestational hypertension with systolic blood pressure < 160 mm Hg, diastolic blood pressure < 105 mm Hg, and no evidence of end-organ damage do not need to be treated with pharmacologic antihypertensive therapy
In pregnant patients with diabetes and preexisting hypertension who are treated with antihypertensive therapy, systolic or diastolic blood pressure targets of 120-160/80-105 mm Hg are suggested in the interest of optimizing long-term maternal health and fetal growth

ADA Standards of Medical Care in Diabetes

The 2022 edition of the ADA’s Standards of Medical Care in Diabetes features several important changes with regard to diabetes screening and management, including the following^{[4, 5]}:

The recommended age at which people should be screened for prediabetes and type 2 diabetes, regardless of the presence or absence of risk factors, has been lowered from age 45 years to age 35 years
It is recommended that all women, regardless of risk factors, be tested for undiagnosed diabetes at the time they are planning to become pregnant or else at their first prenatal visit; gestational diabetes screening should be carried out at 24-28 weeks “in pregnant women not previously found to have diabetes or high-risk abnormal glucose metabolism detected earlier in the current pregnancy”
In persons being screened for diabetes via oral glucose tolerance testing, at least 150 g/day of carbohydrate intake should be assured for 3 days prior to the screen
It is recommended that, in a research study setting or perhaps in first-degree family members of a proband with type 1 diabetes, screening tests that detect autoantibodies to insulin, glutamic acid decarboxylase (GAD), islet antigen 2, or zinc transporter 8 be used to screen for presymptomatic type 1 diabetes
A risk factor for clinical diabetes, the development and persistence of multiple islet autoantibodies may indicate the need “for intervention in the setting of a clinical trial or screening for stage 2 type 1 diabetes”
Persons with prediabetes should be monitored at least annually for the development of type 2 diabetes, with modifications made according to individual risk/benefit assessment
Care goals for adults with overweight/obesity for whom the risk of type 2 diabetes is high “should include weight loss or prevention of weight gain, minimizing progression of hyperglycemia, and attention to cardiovascular risk and associated” comorbidities
If insulin is used in adults with type 2 diabetes, it is recommended that, for better efficacy and durability of treatment effect, combination therapy be employed using a glucagon-like peptide 1 receptor agonist
Consideration may be given to combined therapy employing a sodium–glucose cotransporter 2 inhibitor and a glucagon-like peptide 1 receptor agonist, both with demonstrated cardiovascular benefit, “for additive reduction in the risk of adverse cardiovascular and kidney events” in patients “with type 2 diabetes and established atherosclerotic cardiovascular disease or multiple risk factors for atherosclerotic cardiovascular disease”
If they are capable of using a continuous glucose monitoring (CGM) device safely (either alone or with the aid of a caregiver), youth with type 2 diabetes who are on multiple daily injections or continuous subcutaneous insulin infusion should be offered the option of real-time or intermittently scanned CGM for diabetes management; the patient’s circumstances, desires, and needs should govern the choice of device

ADA guidelines for youth-onset type 2 diabetes

In November 2018, the ADA released a position statement the evaluation and management of youth-onset type 2 diabetes. It includes the following points^[402]:

Severe peripheral and hepatic insulin resistance occurs when type 2 diabetes develops in adolescents with obesity, with peripheral insulin sensitivity being about 50% below that of adolescents who have obesity without diabetes; the disposition index (the mathematically described product of insulin sensitivity and β-cell function) in youth with both obesity and type 2 diabetes is about 85% lower
Risk-based screening should be considered in overweight and obese children over age 10 years or who have commenced puberty
Risk factors for type 2 diabetes in youth should be taken into account, including whether the child’s mother has a history of diabetes or experienced gestational diabetes while pregnant with the child, as well as whether close family members have a history of type 2 diabetes; other risk factors to consider include signs of insulin resistance, as well as the youth’s ethnicity (ie, whether he or she is from a non-Caucasian background, such as African American or Latino)
As part of diagnosis, a panel of pancreatic autoantibodies should be employed to exclude the presence of autoimmune type 1 diabetes
Adherence to medication therapy and the impact of treatment on weight should be taken into account when glucose-lowering agents and other medications are being chosen for patients who are overweight or obese
A chronic approach to lifestyle management should be employed, with education, weight management, exercise, nutrition, and psychological factors emphasized
Education and lifestyle management programs need to be culturally and contextually sensitive
If their BMI is greater than 35 kg/m ², uncontrolled glycemia and/or serious comorbidities are present, and lifestyle and pharmacologic approaches have failed, adolescents with type 2 diabetes may be considered for metabolic surgery (but only by an experienced surgeon and only in tandem with input from a multidisciplinary team that also includes an endocrinologist, a nutritionist, a behavioral health specialist, and a nurse)
A transfer to adult care should be arranged only when the patient and provider deem it appropriate

ADA/EASD recommendations on hyperglycemia management

In October 2018, in an update to previous position statements, the ADA and the European Association for the Study of Diabetes (EASD) released new recommendations regarding adults with type 2 diabetes. The guidelines, on the management of hyperglycemia, include the following^[403]:

Providers and health-care systems should prioritize the delivery of patient-centered care
All people with type 2 diabetes should be offered access to ongoing diabetes self-management education and support (DSMES) programs
Facilitating medication adherence should be specifically considered when selecting glucose-lowering medications
Among patients with type 2 diabetes who have established atherosclerotic cardiovascular disease (ASCVD), sodium-glucose cotransporter–2 (SGLT2) inhibitors or glucacon-like peptide 1 (GLP-1) receptor agonists with proven cardiovascular benefit are recommended as part of glycemic management
Among patients with ASCVD in whom heart failure coexists or is of special concern, SGLT2 inhibitors are recommended
For patients with type 2 diabetes and chronic kidney disease (CKD), with or without CVD, consider the use of an SGLT2 inhibitor shown to reduce CKD progression or, if contraindicated or not preferred, a GLP-1 receptor agonist shown to reduce CKD progression
An individualized program of medical nutrition therapy (MNT) should be offered to all patients
All overweight and obese patients with diabetes should be advised of the health benefits of weight loss and encouraged to engage in a program of intensive lifestyle management, which may include food substitution
Increased physical activity improves glycemic control and should be encouraged in all people with type 2 diabetes
Metabolic surgery is a recommended treatment option for adults with type 2 diabetes and 1) a body mass index (BMI) of 40.0 kg/m ² or higher (BMI of 37.5 kg/m ² or higher in people of Asian ancestry) or 2) a BMI of 35.0-39.9 kg/m ² (32.5-37.4 kg/m ²in people of Asian ancestry) who do not achieve durable weight loss and improvement in comorbidities with reasonable nonsurgical methods
Metformin is the preferred initial glucose-lowering medication for most people with type 2 diabetes
The stepwise addition of glucose-lowering medication is generally preferred to initial combination therapy
The selection of medication added to metformin is based on patient preference and clinical characteristics; important clinical characteristics include the presence of established ASCVD and other comorbidities such as heart failure or CKD; the risk for specific adverse medication effects, particularly hypoglycemia and weight gain; and safety, tolerability, and cost
Intensification of treatment beyond dual therapy to maintain glycemic targets requires consideration of the impact of medication side effects on comorbidities, as well as the burden of treatment and cost
In patients who need the greater glucose-lowering effect of an injectable medication, GLP-1 receptor agonists are the preferred choice to insulin; for patients with extreme and symptomatic hyperglycemia, insulin is recommended
Patients who are unable to maintain glycemic targets on basal insulin in combination with oral medications can have treatment intensified with GLP-1 receptor agonists, SGLT2 inhibitors, or prandial insulin
Access, treatment cost, and insurance coverage should all be considered when selecting glucose-lowering medications

Diabetes Canada guidelines for family physicians

The following clinical practice guidelines for family physicians caring for patients with type 2 diabetes mellitus were released in 2018 by Diabetes Canada^[404]:

Patients without clinical cardiovascular disease (CVD) who fail to achieve glycemic targets with existing antihyperglycemic drug therapy and in whom reduced risk of hypoglycemia and weight gain are priorities should be considered for add-on treatment with incretin agents (dipeptidyl peptidase IV [DPP-4] inhibitors or glucagonlike peptide–1 [GLP-1] agonists) or selective sodium-glucose transporter–2 (SGLT-2) inhibitors, as alternatives to insulin secretagogues, insulin, and thiazolidinediones (TZDs)
Patients without clinical cardiovascular disease (CVD) who fail to achieve glycemic targets with existing antihyperglycemic drug therapy should additionally receive an antihyperglycemic agent with demonstrated cardiovascular (CV) outcome benefit (such as empagliflozin or liraglutide) to decrease the likelihood of major CV events
In patients who fail to achieve glycemic targets with existing noninsulin antihyperglycemic drug therapy, consider adding a once-daily basal insulin regimen as an alternative to premixed insulin or bolus-only regimens, as a means of reducing weight gain and hypoglycemia
To decrease the likelihood of nocturnal and symptomatic hypoglycemia, long-acting insulin analogues should be considered as an alternative to neutral protamine Hagedorn (NPH) insulin
Patients receiving insulin who fail to achieve glycemic targets should undergo dose adjustment or the administration of additional antihyperglycemic medication (noninsulin or bolus insulin), with the following kept in mind: (1) to achieve better glycemic control with weight loss and a lower hypoglycemia risk than with single- or multiple-bolus insulin injections, consider administering a GLP-1 agonist as add-on treatment prior to initiating bolus insulin or intensifying insulin therapy; (2) consider add-on therapy with an SGLT-2 inhibitor as a means of improving glycemic control with weight loss and reducing the likelihood of hypoglycemia, compared with the administration of additional insulin; (3) consider add-on therapy with a DPP-4 inhibitor as a means of improving glycemic control without weight gain or greater likelihood of hypoglycemia, compared with the administration of additional insulin
All persons with diabetes should engage in a comprehensive, multifaceted approach to CV risk reduction, including the following: (1) hemoglobin A1c (HbA1c) target of ≤7.0% instigated early in the course of diabetes; (2) systolic and diastolic blood pressure (BP) of < 130 mm Hg and < 80 mm Hg, respectively; (3) additional vascular protective medications in most adults with diabetes; (4) reaching and maintaining a healthy weight; (5) engaging in healthy nutrition; (6) regular physical activity; (7) smoking cessation
To lower the CV risk in adults with type 1 or type 2 diabetes, angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) should be employed at vascular-protective doses when any of the following exist (note: among women with childbearing potential, ACE inhibitors, ARBs, or statins should be used only in the presence of reliable contraception): (1) clinical CVD, (2) age >55 y with an additional CV risk factor or end organ damage (albuminuria, retinopathy, left ventricular hypertrophy), (3) microvascular complications
To prevent CV events in patients with established CVD, employ low-dose acetylsalicylic acid (ASA) therapy (81-162 mg)
The failure of existing antihyperglycemic drug therapy to achieve glycemic targets In adults with type 2 diabetes with clinical CVD should prompt the addition of an antihyperglycemic agent with demonstrated CV outcome benefit (such as empagliflozin or liraglutide) to lower the risk of major CV events
The failure of existing antihyperglycemic drug therapy to achieve glycemic targets in older people with type 2 diabetes who have no other complex comorbidities (but who do have clinical CVD) can prompt the addition of an antihyperglycemic agent with demonstrated CV outcome benefit (such as empagliflozin or liraglutide) to lower the risk of major CV events
Interprofessional teams should provide collaborative care for individuals with diabetes and depression to improve the following: (1) depressive symptoms, (2) adherence to the use of antidepressant and noninsulin antihyperglycemic medications, (3) glycemic control
Psychosocial interventions, including the following, should be woven into diabetes care plans: (1) motivational interventions, (2) stress management strategies, (3) coping skills training, (4) family therapy, (5) case management
To achieve better glycemic control and lower the risk of CVD and overall mortality, patients with diabetes should, over the course of at least 3 days per week, engage in a minimum of 150 minutes of moderate- to vigorous-intensity aerobic exercise, with no more than 2 consecutive nonexercise days; glycemic control can also be aided, though to a lesser extent, by 90-140 minutes per week of exercise or planned physical activity
In patients with type 2 diabetes who are able to perform interval training, this form of physical activity (in which short periods of vigorous exercise are alternated with short recovery periods employing low to moderate intensity or rest) can be recommended to aid cardiorespiratory fitness
Resistance exercise should be performed by patients with diabetes, including elderly ones, two or (preferably) three times per week
As a means of increasing physical activity and improving HbA1c levels, a patient with diabetes and his/her health-care provider should collaborate on setting exercise goals, resolving potential barriers to exercise, and determining where and when the patient should exercise, with self-monitoring performed
Timely education aimed at improving self-care practices and behavior should be offered to patients with diabetes
Self-management aimed at improving glycemic control can be technologically supported, including with Internet-based computer programs and glucose-monitoring systems, brief text messages, and mobile applications

Endocrine Society guidelines on diabetes management in older adults

In 2019, the Endocrine Society released the following clinical practice guidelines on the diagnosis and management of diabetes and its comorbidities in older adults^{[405, 406]}:

Screening for diabetes or prediabetes with the fasting plasma glucose test or HbA1c analysis is recommended for patients aged 65 years or older without known diabetes
A 2-hour glucose post–oral glucose tolerance test is suggested for patients aged 65 years or older without known diabetes in whom results from fasting plasma glucose or HbA1c analysis have indicated that prediabetes is present
To delay the onset of diabetes, it is recommended that patients aged 65 years or older with prediabetes adopt a lifestyle in line with that presented in the Diabetes Prevention Program
It is recommended that patients aged 65 years or older with diabetes participate in outpatient regimens specifically conceived to minimize hypoglycemia
Lifestyle modification is recommended as the first-line treatment for hyperglycemia in ambulatory individuals aged 65 years or older with diabetes
Nutritional status assessment for the detection and management of malnutrition is recommended in patients aged 65 years or older with diabetes
It is recommended that along with lifestyle changes, patients aged 65 years or older with diabetes undergo initial oral drug treatment with metformin, for glycemic management; significant kidney function impairment (estimated glomerular filtration rate < 30 mL/min/1.73 m ²) or gastrointestinal intolerance should preclude implementation of this recommendation
If metformin therapy and lifestyle changes have not led a patient aged 65 years or older with diabetes to achieve his/her glycemic target, it is recommended that metformin treatment be combined with therapy employing other oral or injectable agents and/or insulin
To reduce the risk of cardiovascular disease outcomes, stroke, and progressive chronic kidney disease, it is recommended that the target blood pressure in patients aged 65-85 years with diabetes be 140/90 mm Hg
It is recommended that an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker be administered as first-line therapy in patients aged 65 years or older with diabetes and hypertension
Statin therapy and an annual lipid profile are recommended in patients aged 65 years or older with diabetes to reduce absolute cardiovascular disease events and all-cause mortality
For detection of retinal disease, annual comprehensive eye examinations are recommended for patients aged 65 years or older with diabetes
It is recommended that patients aged 65 years or older with diabetes who are not on dialysis be screened annually for chronic kidney disease, with determination of the estimated glomerular filtration rate and urine albumin-to-creatinine ratio

ESC guidelines on CVD management and prevention

In September 2019, the European Society of Cardiology (ESC), in collaboration with the European Association for the Study of Diabetes (EASD), released updated guidelines aimed at managing and preventing cardiovascular disease (CVD) in patients with diabetes or prediabetes. Patient CV risk is classified in the guidelines as follows^[407]:

Medium CV risk - Young patients without other CV risk factors who have had diabetes for less than 10 years
High CV risk - Patients who lack target-organ damage but have had diabetes for over 10 years and in whom at least one other risk factor exists
Very high CV risk - Patients with CVD or target-organ damage or in whom type 1 diabetes has been present for more than 20 years

The recommendations include the following^[407]:

In drug-naïve patients with type 2 diabetes and established CVD, administration of a sodium-glucose cotransporter–2 (SGLT-2) inhibitor or glucagonlike peptide-1 (GLP-1) receptor agonist should be immediately initiated or added to existing metformin treatment
Based on a cardiovascular outcome trial (CVOT), it is recommended that aspirin be used in high- and very high–risk patients (on an individual basis) but not in moderate-risk patients
Very high–risk patients in whom low-density lipoprotein (LDL) cholesterol levels are persistently high even with maximal statin and ezetimibe therapy or who have statin intolerance should undergo proprotein convertase subtilisin/kexin type 9 (PCSK-9) inhibitor treatment
An HbA1c level of under 7% is advised, particularly in young adults who have had diabetes for only a short time
In patients with medium, high, and very high CV risk, lipid targets of 2.5 mmol/L, 1.8 mmol/L, and below 1.4 mmol/L, respectively, are recommended

Expert panel: management of diabetes in patients with coronavirus disease 2019 (COVID-19)

Recommendations for the management of diabetes in patients with COVID-19 were published on April 23, 2020, by an international panel of diabetes experts.^{[408, 409]}

Regarding infection prevention and outpatient care:

Patients with diabetes, particularly those with type I diabetes mellitus, should be sensitized to the importance of optimal metabolic control
Current therapy should, if appropriate, be optimized
Telemedicine and connected health models should be used, if possible, to maintain maximal self-containment

All patients hospitalized with COVID-19 should be monitored for new-onset diabetes.

Regarding management in the intensive care unit (ICU) of infected patients with diabetes:

Plasma glucose monitoring, electrolytes, pH, blood ketones, or β-hydroxybutyrate
There is liberal indication for early intravenous insulin therapy in severe disease courses (acute respiratory distress syndrome, hyperinflammation) for exact titration, with variable subcutaneous resorption avoided, and management of commonly encountered very high insulin consumption

Therapeutic goals include the following:

Plasma glucose concentration: 4-8 mmol/L (72-144 mg/dL) for outpatients or 4-10 mmol/L (72-180 mg/dL) for inpatients/intensive care, with, for frail individuals, the lower value possibly adjusted upward to 5 mmol/L (90 mg/dL)
A1c < 53 mmol/mol (7%)
Continuous glucose monitoring/flash glucose monitoring targets: Time-in-range (3.9-10 mmol/L) >70% of time (or >50% in frail and older patients)
Hypoglycemia < 3.9 mmol/L (< 70 mg/dL): < 4% (< 1% in frail and older patients)

The panel advises stopping administration of metformin and sodium-glucose cotransporter–2 (SGLT2) inhibitors in patients with COVID-19 and type 2 diabetes in order to lower the risk of acute metabolic decompensation.

Fluid balance requires considerable care, “as there is a risk that excess fluid can exacerbate pulmonary edema in the severely inflamed lung.”

Potassium balance requires careful consideration in the context of insulin treatment, “as hypokalemia is a common feature in COVID-19,” with initiation of insulin possibly exacerbating it.

The panel recommends screening for hyperinflammation, owing to the possibility of increased risk for cytokine storm and severe COVID-19 in patients with type 2 diabetes and fatty liver disease.

ADA guidelines on pharmacologic means of glycemic therapy in type 2 diabetes

In September 2020, the ADA published clinical guidelines on pharmacologic means of glycemic therapy in type 2 diabetes. They include the following:

Metformin therapy is the preferred initial pharmacologic treatment for type 2 diabetes
To extend the time to treatment failure, early combination therapy can, in some patients, be considered at treatment initiation
If evidence of ongoing catabolism exists (weight loss), if symptoms of hyperglycemia are present, or when HbA1c or blood glucose levels are very high (HbA1c >10% [86 mmol/mol], blood glucose ≥16.7 mmol/L [300 mg/dL]), consider early introduction of insulin
Employ a patient-centered approach to guide the choice of pharmacologic agents, with factors such as cardiovascular comorbid conditions, hypoglycemia risk, impact on weight, cost, risk for side effects, and patient preferences taken into account
It is recommended that a sodium-glucose cotransporter–2 (SGLT2) inhibitor or glucagonlike peptide-1 receptor agonist (GLP-1 RA) with demonstrated cardiovascular disease benefit be administered to patients with type 2 diabetes who have established atherosclerotic cardiovascular disease (ASCVD), indicators of high ASCVD risk, established kidney disease, or heart failure
The use of GLP-1 RAs, when possible, is preferred over insulin therapy in the treatment of patients with type 2 diabetes who need greater glucose reduction than oral agents can provide
Reevaluate the patient’s medication regimen and medication-taking behavior every 3 to 6 months, adjusting them as needed to incorporate specific factors that affect treatment choice

AACE guidelines for use of advanced technology

In May 2021, the American Association of Clinical Endocrinology (AACE) released guidelines on the use of advanced technologies in diabetes management. The following recommendations are among those published.^{[410, 411]}

The percentage of time in range (%TIR) and below range (%TBR) should serve as a starting point for the evaluation of the quality of glycemic control and form the basis for therapy adjustment.

For all persons with diabetes who are undergoing intensive insulin therapy (ie, three or more injections of insulin per day or treatment with an insulin pump), continuous glucose monitoring (CGM) is strongly recommended. For individuals on insulin therapy for whom success with CGM has been limited (or for those who are unable or unwilling to use CGM), structured self-monitoring of blood glucose (SMBG) is recommended. CGM is recommended for all individuals with problematic hypoglycemia (frequent/severe hypoglycemia, nocturnal hypoglycemia, hypoglycemia unawareness), for children/adolescents with type 1 diabetes; for pregnant women with type 1 or type 2 diabetes treated with intensive insulin therapy, and for women with gestational diabetes mellitus (GDM) on insulin therapy. CGM may be recommended for women with GDM who are not undergoing insulin treatment and for individuals with type 2 diabetes who are undergoing less intensive insulin therapy.

For persons with diabetes who have problematic hypoglycemia (frequent/severe hypoglycemia, nocturnal hypoglycemia, hypoglycemia unawareness) and need predictive alarms/alerts, real-time CGM (rtCGM) should be recommended over intermittently scanned CGM (isCGM). Consideration should also be given, however, to a patient’s lifestyle and to other factors.

The management of persons with diabetes who meet one or more of the following criteria should entail the use of diagnostic/professional CGM:

Newly diagnosed with diabetes mellitus
Not using CGM
No access to personal CGM, despite having problematic hypoglycemia
Persons with type 2 diabetes who, although undergoing non-insulin therapy, would derive educational benefit from episodic use of CGM
Persons who, before committing to daily use of CGM, wish to know more about it

Importantly, continued adjunctive use of SMBG must be employed by patients who are using “masked” or “blinded” diagnostic/professional CGM, to assist in daily diabetes self-care.

Persons with diabetes in whom glycemic targets are being reached with minimal TBR, infrequent episodes of symptomatic hypoglycemia are being reported, and SMBG is being used on a regular basis (at least 4 times daily for persons with type 1 diabetes) could employ an insulin pump without CGM.

In all persons with diabetes who are undergoing intensive insulin management but who prefer to forgo the use of automated insulin suspension/dosing systems or have no access to them, use of an insulin pump with CGM or a sensor-augmented pump (SAP) is recommended.

To reduce hypoglycemia’s severity and duration in persons with type 1 diabetes, low-glucose suspend (LGS) is strongly recommended; for mitigation of hypoglycemia in these patients, predictive low-glucose suspend (PLGS) is strongly recommended.

It is strongly recommended that all persons with type 1 diabetes use automated insulin dosing (AID) systems; these have been shown to raise the TIR, especially in the overnight period, without increasing the hypoglycemia risk.

In persons with diabetes who are hospitalized but are suffering no cognitive impairment, consideration should be given to the continuation of CGM and/or continuous subcutaneous insulin injection (CSII) (insulin pump, SAP, LGS/PLGS). The presence of a family member who is knowledgeable and educated in the use of these devices or the availability of a specialized inpatient diabetes team for advice and support is ideal in such situations.

To enable persons aged 65 years or older with insulin-requiring diabetes to improve glycemic control, reduce episodes of severe hypoglycemia, and improve quality of life, use of rtCGM is recommended. Owing, however, to this population’s increased comorbidities and lowered capacity to detect and counter-regulate against severe hypoglycemia, glycemic goals should be individualized.

As a means of tracking glucose before, during, and after exercise in persons with diabetes; monitoring the glycemic response to exercise; and helping to direct insulin and carbohydrate consumption to prevent the development of hypoglycemia and hyperglycemia, clinicians should prescribe CGM.

It is strongly recommended that telemedicine be used in the treatment of diabetes, provision of diabetes education, remote monitoring of glucose and/or insulin data, and improvement of diabetes-related outcomes/control.

As a means of teaching/reinforcing diabetes self-management skills, encouraging engagement, and supporting/encouraging desired health behaviors, clinically validated smartphone applications should be recommended to persons with diabetes.

Comprehensive training in the proper use and care of insulin delivery technology should be provided to all persons with diabetes using that equipment.

It is strongly recommended that, in the absence of pump therapy, FDA-cleared and clinically validated smartphone bolus calculators be used to reduce the frequency of hypoglycemia or severe postprandial hyperglycemia.

SID/AMD treatment guidelines

Clinical guidelines on the treatment of type 2 diabetes mellitus were published in March 2022 by the Società Italiana di Diabetologia (SID) and the Associazione Medici Diabetologi (AMD). They include the following^[412]:

In patients with type 2 diabetes who are undergoing treatment with drugs that can induce hypoglycemia, it is recommended that the target hemoglobin A1c (HbA1c) level be between 49 mmol/mol (6.6%) and 58 mmol/mol (7.5%)
In patients with type 2 diabetes who are undergoing treatment with drugs that cannot induce hypoglycemia, it is recommended that the target HbA1c level be below 53 mmol/mol (7%)
It is suggested that structured medical nutrition therapy (made up of nutritional assessment, diagnosis, intervention, and monitoring) be employed in type 2 diabetes treatment
Regular physical exercise is suggested for type 2 diabetes treatment
Combined (aerobic and resistance) training, rather than aerobic training alone, is suggested for type 2 diabetes treatment
In patients with type 2 diabetes who have not had previous cardiovascular events, metformin is recommended as a first-line, long-term treatment; as second-line agents, sodium-glucose cotransporter-2 (SGLT-2) inhibitors or glucagon-like peptide-1 (GLP-1) receptor agonists are recommended, while as third-line treatments, consideration should be given to pioglitazone, dipeptidyl peptidase 4 (DPP-4) inhibitors, acarbose, and insulin
In patients with type 2 diabetes with previous cardiovascular events but without heart failure, the use of metformin, SGLT-2 inhibitors, or GLP-1 receptor agonists is recommended as first-line, long-term treatment; as second-line treatments, consideration should be given to DPP-4 inhibitors, pioglitazone, acarbose, and insulin
In patients with type 2 diabetes who have suffered previous heart failure, SGLT-2 inhibitors are recommended for first-line, long-term treatment; consideration should be given to GLP-1 receptor agonists and metformin as second-line treatments, and to DPP-4 inhibitors, acarbose, and insulin as third-line treatments
It is recommended that all patients with type 2 diabetes who require treatment with basal insulin receive basal insulin analogues rather than neutral protamine Hagedorn (NPH) insulin
It is not suggested that in patients with type 2 diabetes who are on basal-bolus insulin therapy, continuous glucose monitoring (continuous or on demand) instead of self-monitoring of blood glucose be practiced

Medication

[Guideline] Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010 Jan. 33 Suppl 1:S62-9. [QxMD MEDLINE Link]. [Full Text].
[Guideline] American Diabetes Association. Standards of medical care in diabetes--2012. Diabetes Care. 2012 Jan. 35 Suppl 1:S11-63. [QxMD MEDLINE Link].
U.S. Preventive Services Task Force. Screening for Type 2 Diabetes Mellitus in Adults. Available at http://www.ahrq.gov/clinic/uspstf/uspsdiab.htm.
[Guideline] Tucker ME. Diabetes Care 2022: Screen More, Personalize, Use Technology. Medscape Medical News. 2021 Dec 20. [Full Text].
[Guideline] American Diabetes Association. Introduction: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 Jan 1. 45 (Supplement_1):S1-S2. [QxMD MEDLINE Link]. [Full Text].
Keller DM. New EASD/ADA Position Paper Shifts Diabetes Treatment Goals. Medscape Medical News. Available at http://www.medscape.com/viewarticle/771989. Accessed: October 15, 2012.
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012 Jun. 55(6):1577-96. [QxMD MEDLINE Link].
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012 Jun. 35(6):1364-79. [QxMD MEDLINE Link]. [Full Text].
Tucker ME. New diabetes guidelines ease systolic blood pressure target. December 20, 2012. Medscape Medical News. Available at http://www.medscape.com/viewarticle/776543. Accessed: January 8, 2013.
[Guideline] American Diabetes Association Professional Practice Committee. American Diabetes Association clinical practice recommendations: 2013. Diabetes Care. January 2013. 36 (suppl 1):S1-S110. [Full Text].
Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 2003 Jan. 26 Suppl 1:S5-20. [QxMD MEDLINE Link].
Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2017. 2017. Available at https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf.
Harrison P. Almost Half the US Population Has Diabetes or Its Precursor. Medscape Medical News. 2017 Jul 19. [Full Text].
Unger RH, Orci L. Paracrinology of islets and the paracrinopathy of diabetes. Proc Natl Acad Sci U S A. 2010 Sep 14. 107(37):16009-12. [QxMD MEDLINE Link]. [Full Text].
Philippe MF, Benabadji S, Barbot-Trystram L, Vadrot D, Boitard C, Larger E. Pancreatic volume and endocrine and exocrine functions in patients with diabetes. Pancreas. 2011 Apr. 40(3):359-63. [QxMD MEDLINE Link].
Bacha F, Lee S, Gungor N, Arslanian SA. From pre-diabetes to type 2 diabetes in obese youth: pathophysiological characteristics along the spectrum of glucose dysregulation. Diabetes Care. 2010 Oct. 33(10):2225-31. [QxMD MEDLINE Link]. [Full Text].
Hansen KB, Vilsboll T, Bagger JI, Holst JJ, Knop FK. Increased postprandial GIP and glucagon responses, but unaltered GLP-1 response after intervention with steroid hormone, relative physical inactivity, and high-calorie diet in healthy subjects. J Clin Endocrinol Metab. 2011 Feb. 96(2):447-53. [QxMD MEDLINE Link].
Wheeler E, Barroso I. Genome-wide association studies and type 2 diabetes. Brief Funct Genomics. 2011 Mar. 10(2):52-60. [QxMD MEDLINE Link].
Billings LK, Florez JC. The genetics of type 2 diabetes: what have we learned from GWAS? Ann N Y Acad Sci. 2010 Nov;1212:59-77. [Full Text].
Nielsen EM, Hansen L, Carstensen B, Echwald SM, Drivsholm T, Glumer C, et al. The E23K variant of Kir6.2 associates with impaired post-OGTT serum insulin response and increased risk of type 2 diabetes. Diabetes. 2003 Feb. 52(2):573-7. [QxMD MEDLINE Link].
Ukkola O, Sun G, Bouchard C. Insulin-like growth factor 2 (IGF2 ) and IGF-binding protein 1 (IGFBP1) gene variants are associated with overfeeding-induced metabolic changes. Diabetologia. 2001 Dec. 44(12):2231-6. [QxMD MEDLINE Link].
Lindgren CM, McCarthy MI. Mechanisms of disease: genetic insights into the etiology of type 2 diabetes and obesity. Nat Clin Pract Endocrinol Metab. 2008 Mar. 4(3):156-63. [QxMD MEDLINE Link].
Sladek R, Rocheleau G, Rung J, Dina C, Shen L, Serre D, et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature. 2007 Feb 22. 445(7130):881-5. [QxMD MEDLINE Link].
Sandhu MS, Weedon MN, Fawcett KA, Wasson J, Debenham SL, Daly A, et al. Common variants in WFS1 confer risk of type 2 diabetes. Nat Genet. 2007 Aug. 39(8):951-3. [QxMD MEDLINE Link]. [Full Text].
Saxena R, Hivert MF, Langenberg C, Tanaka T, Pankow JS, Vollenweider P, et al. Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat Genet. 2010 Feb. 42(2):142-8. [QxMD MEDLINE Link]. [Full Text].
Chiefari E, Tanyolac S, Paonessa F, Pullinger CR, Capula C, Iiritano S, et al. Functional variants of the HMGA1 gene and type 2 diabetes mellitus. JAMA. 2011 Mar 2. 305(9):903-12. [QxMD MEDLINE Link].
Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, McCabe E, et al. Metabolite profiles and the risk of developing diabetes. Nat Med. 2011 Apr. 17(4):448-53. [QxMD MEDLINE Link]. [Full Text].
Testa R, Olivieri F, Sirolla C, Spazzafumo L, Rippo MR, Marra M, et al. Leukocyte telomere length is associated with complications of type 2 diabetes mellitus. Diabet Med. 2011 Nov. 28(11):1388-94. [QxMD MEDLINE Link].
Krssak M, Winhofer Y, Gobl C, Bischof M, Reiter G, Kautzky-Willer A, et al. Insulin resistance is not associated with myocardial steatosis in women. Diabetologia. 2011 Jul. 54(7):1871-8. [QxMD MEDLINE Link].
Leiter LA, Lundman P, da Silva PM, Drexel H, Junger C, Gitt AK. Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study. Diabet Med. 2011 Nov. 28(11):1343-51. [QxMD MEDLINE Link].
Stern MP. Do non-insulin-dependent diabetes mellitus and cardiovascular disease share common antecedents?. Ann Intern Med. 1996 Jan 1. 124(1 Pt 2):110-6. [QxMD MEDLINE Link].
Haffner SM, D'Agostino R Jr, Mykkanen L, Tracy R, Howard B, Rewers M, et al. Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study. Diabetes Care. 1999 Apr. 22(4):562-8. [QxMD MEDLINE Link].
Busko M. Gray-matter atrophy may drive cognitive decline in diabetes. Medscape Medical News. August 22, 2013. [Full Text].
Moran C, Phan TG, Chen J, et al. Brain atrophy in type 2 diabetes: regional distribution and influence on cognition. Diabetes Care. 2013 Aug 12. [QxMD MEDLINE Link].
Brooks M. Depression accelerates cognitive decline in type 2 diabetes. Medscape Medical News. October 17, 2013. [Full Text].
Sullivan MD, Katon WJ, Lovato LC, Miller ME, Murray AM, Horowitz KR, et al. Association of Depression With Accelerated Cognitive Decline Among Patients With Type 2 Diabetes in the ACCORD-MIND Trial. JAMA Psychiatry. 2013 Oct 1. 70(10):1041-7. [QxMD MEDLINE Link].
Garg S, Kim L, Whitaker M, et al. Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 — COVID-NET, 14 States, March 1–30, 2020. MMWR. 2020 Apr 8. [Full Text].
Stokes EK, Zambrano LD, Anderson KN, et al. Coronavirus Disease 2019 Case Surveillance — United States, January 22–May 30, 2020. MMWR Morb Mortal Wkly Rep. 2020 Jun 15. [Full Text].
Franki R. Comorbidities Increase COVID-19 Deaths by Factor of 12. Medscape Medical News. 2020 Jun 17. [Full Text].
Zoler ML. Cleaner data confirm severe COVID-19 link to diabetes, hypertension. MDedge Cardiology News. 2020 Jul 27. [Full Text].
Barrera FJ, Shekhar S, Wurth R, et al. Prevalence of Diabetes and Hypertension and their Associated Risks for Poor Outcomes in Covid-19 Patients. J Endocr Soc. 2020 Jul 21. [Full Text].
King J. Inflammatory markers may explain COVID-19, diabetes dynamic. MDedge. 2020 Apr 15. [Full Text].
Guo W, Li M, Dong Y, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev. 2020 Mar 31. e3319. [QxMD MEDLINE Link]. [Full Text].
Ahlqvist E, Storm P, Karajamaki A, et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol. 2018 Mar 1. [QxMD MEDLINE Link].
Davenport L. Diabetes Consists of Five Types, Not Two, Say Researchers. Medscape Medical News. 2018 Mar 1. [Full Text].
Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004 Jan 10. 363(9403):157-63. [QxMD MEDLINE Link].
Wei GS, Coady SA, Goff DC Jr, Brancati FL, Levy D, Selvin E, et al. Blood pressure and the risk of developing diabetes in african americans and whites: ARIC, CARDIA, and the framingham heart study. Diabetes Care. 2011 Apr. 34(4):873-9. [QxMD MEDLINE Link]. [Full Text].
Dabelea D, Pettitt DJ, Hanson RL, Imperatore G, Bennett PH, Knowler WC. Birth weight, type 2 diabetes, and insulin resistance in Pima Indian children and young adults. Diabetes Care. 1999 Jun. 22(6):944-50. [QxMD MEDLINE Link].
Yarbrough DE, Barrett-Connor E, Kritz-Silverstein D, Wingard DL. Birth weight, adult weight, and girth as predictors of the metabolic syndrome in postmenopausal women: the Rancho Bernardo Study. Diabetes Care. 1998 Oct. 21(10):1652-8. [QxMD MEDLINE Link].
Li Y, Qi Q, Workalemahu T, Hu FB, Qi L. Birth Weight, Genetic Susceptibility, and Adulthood Risk of Type 2 Diabetes. Diabetes Care. 2012 Aug 24. [QxMD MEDLINE Link].
Slining MM, Kuzawa CW, Mayer-Davis EJ, Adair LS. Evaluating the indirect effect of infant weight velocity on insulin resistance in young adulthood: a birth cohort study from the Philippines. Am J Epidemiol. 2011 Mar 15. 173(6):640-8. [QxMD MEDLINE Link]. [Full Text].
American Society for Metabolic an Bariatric Surgery. Type 2 Diabetes and Metabolic Surgery. Available at https://asmbs.org/resources/type-2-diabetes-and-metabolic-surgery-fact-sheet#:~:text=Obesity%20%E2%80%93%20medically%20defined%20as%20a,BMI%20of%20at%20least%2025).. October 2018; Accessed: March 6, 2021.
Wang J, Luben R, Khaw KT, Bingham S, Wareham NJ, Forouhi NG. Dietary energy density predicts the risk of incident type 2 diabetes: the European Prospective Investigation of Cancer (EPIC)-Norfolk Study. Diabetes Care. 2008 Nov. 31(11):2120-5. [QxMD MEDLINE Link]. [Full Text].
Cameron NA, Petito LC, McCabe M, et al. Quantifying the Sex-Race/Ethnicity-Specific Burden of Obesity on Incident Diabetes Mellitus in the United States, 2001 to 2016: MESA and NHANES. J Am Heart Assoc. 2021 Feb 16. 10 (4):e018799. [QxMD MEDLINE Link]. [Full Text].
Zoler ML. Obesity Pegged as Diabetes Cause in Almost Half of US Cases. Medscape Medical News. 2021 Feb 18. [Full Text].
Hectors TL, Vanparys C, van der Ven K, Martens GA, Jorens PG, Van Gaal LF, et al. Environmental pollutants and type 2 diabetes: a review of mechanisms that can disrupt beta cell function. Diabetologia. 2011 Jun. 54(6):1273-90. [QxMD MEDLINE Link].
Pauza AG, Thakkar P, Tasic T, et al. GLP1R Attenuates Sympathetic Response to High Glucose via Carotid Body Inhibition. Circ Res. 2022 Feb 1. CIRCRESAHA121319874. [QxMD MEDLINE Link]. [Full Text].
Sweet pressure – scientists discover link between high blood pressure and diabetes. University of Bristol. Available at https://www.bristol.ac.uk/news/2022/february/blood-pressure-diabetes.html. February 1, 2022; Accessed: February 2, 2022.
de Miguel-Yanes JM, Shrader P, Pencina MJ, Fox CS, Manning AK, Grant RW, et al. Genetic risk reclassification for type 2 diabetes by age below or above 50 years using 40 type 2 diabetes risk single nucleotide polymorphisms. Diabetes Care. 2011 Jan. 34(1):121-5. [QxMD MEDLINE Link]. [Full Text].
Winckler W, Weedon MN, Graham RR, McCarroll SA, Purcell S, Almgren P, et al. Evaluation of common variants in the six known maturity-onset diabetes of the young (MODY) genes for association with type 2 diabetes. Diabetes. 2007 Mar. 56(3):685-93. [QxMD MEDLINE Link].
Molven A, Ringdal M, Nordbo AM, Raeder H, Stoy J, Lipkind GM, et al. Mutations in the insulin gene can cause MODY and autoantibody-negative type 1 diabetes. Diabetes. 2008 Apr. 57(4):1131-5. [QxMD MEDLINE Link].
Neve B, Fernandez-Zapico ME, Ashkenazi-Katalan V, Dina C, Hamid YH, Joly E, et al. Role of transcription factor KLF11 and its diabetes-associated gene variants in pancreatic beta cell function. Proc Natl Acad Sci U S A. 2005 Mar 29. 102(13):4807-12. [QxMD MEDLINE Link]. [Full Text].
Raeder H, Johansson S, Holm PI, Haldorsen IS, Mas E, Sbarra V, et al. Mutations in the CEL VNTR cause a syndrome of diabetes and pancreatic exocrine dysfunction. Nat Genet. 2006 Jan. 38(1):54-62. [QxMD MEDLINE Link].
Plengvidhya N, Kooptiwut S, Songtawee N, Doi A, Furuta H, Nishi M, et al. PAX4 mutations in Thais with maturity onset diabetes of the young. J Clin Endocrinol Metab. 2007 Jul. 92(7):2821-6. [QxMD MEDLINE Link].
Borowiec M, Liew CW, Thompson R, Boonyasrisawat W, Hu J, Mlynarski WM, et al. Mutations at the BLK locus linked to maturity onset diabetes of the young and beta-cell dysfunction. Proc Natl Acad Sci U S A. 2009 Aug 25. 106(34):14460-5. [QxMD MEDLINE Link]. [Full Text].
Edghill EL, Bingham C, Ellard S, Hattersley AT. Mutations in hepatocyte nuclear factor-1beta and their related phenotypes. J Med Genet. 2006 Jan. 43(1):84-90. [QxMD MEDLINE Link]. [Full Text].
van den Ouweland JM, Lemkes HH, Ruitenbeek W, Sandkuijl LA, de Vijlder MF, Struyvenberg PA, et al. Mutation in mitochondrial tRNA(Leu)(UUR) gene in a large pedigree with maternally transmitted type II diabetes mellitus and deafness. Nat Genet. 1992 Aug. 1(5):368-71. [QxMD MEDLINE Link].
Castellino AM. Genetically Lowered Birth Weight May Cause Type 2 Diabetes. Medscape Medical News. July 4, 2016. [Full Text].
Wang T, Huang T, Li Y, Zheng Y, Manson JE, Hu FB, et al. Low birthweight and risk of type 2 diabetes: a Mendelian randomisation study. Diabetologia. 2016 Jun 23. [QxMD MEDLINE Link].
Pan A, Lucas M, Sun Q, van Dam RM, Franco OH, Manson JE, et al. Bidirectional association between depression and type 2 diabetes mellitus in women. Arch Intern Med. 2010 Nov 22. 170(21):1884-91. [QxMD MEDLINE Link]. [Full Text].
Nouwen A, Winkley K, Twisk J, Lloyd CE, Peyrot M, Ismail K, et al. Type 2 diabetes mellitus as a risk factor for the onset of depression: a systematic review and meta-analysis. Diabetologia. 2010 Dec. 53(12):2480-6. [QxMD MEDLINE Link]. [Full Text].
Siuta MA, Robertson SD, Kocalis H, Saunders C, Gresch PJ, Khatri V, et al. Dysregulation of the norepinephrine transporter sustains cortical hypodopaminergia and schizophrenia-like behaviors in neuronal rictor null mice. PLoS Biol. 2010 Jun 8. 8(6):e1000393. [QxMD MEDLINE Link]. [Full Text].
Feig DS, Shah BR, Lipscombe LL, Wu CF, Ray JG, Lowe J, et al. Preeclampsia as a risk factor for diabetes: a population-based cohort study. PLoS Med. 2013 Apr. 10(4):e1001425. [QxMD MEDLINE Link]. [Full Text].
Tucker ME. New Global Registry Investigates COVID-19 and New-Onset Diabetes. Medscape Medical News. 2020 Jun 13. [Full Text].
Xie Y, Al-Aly Z. Risks and burdens of incident diabetes in long COVID: a cohort study. Lancet Diabetes Endocrinol. 2022 Mar 21. [Full Text].
Tucker ME. 'Profound Implications': COVID Ups Diabetes Risk 40% a Year Later. Medscape Medical News. 2022 Mar 23. [Full Text].
Tang X, Uhl S, Zhang T, et al. SARS-CoV-2 infection induces beta cell transdifferentiation. Cell Metab. 2021 May 19. [QxMD MEDLINE Link]. [Full Text].
Wu CT, Lidsky PV, Xiao Y, et al. SARS-CoV-2 infects human pancreatic β cells and elicits β cell impairment. Cell Metab. 2021 May 18. [QxMD MEDLINE Link]. [Full Text].
Barrett CE, Koyama AK, Alvarez P, et al. Risk for Newly Diagnosed Diabetes >30 Days After SARS-CoV-2 Infection Among Persons Aged MMWR Morb Mortal Wkly Rep</i>. 2022 Jan 7. 71:[Full Text].
Tucker ME. COVID-19 Associated With Increased Diabetes Risk in Youth. Medscape Medical News. 2022 Jan 10. [Full Text].
Cromer SJ, Colling C, Schatoff D, et al. Newly diagnosed diabetes vs. pre-existing diabetes upon admission for COVID-19: Associated factors, short-term outcomes, and long-term glycemic phenotypes. J Diabetes Complications. 2022 Feb 4. 108145. [QxMD MEDLINE Link]. [Full Text].
Centers for Disease Control and Prevention. National Diabetes Statistics Report. CDC. Available at https://www.cdc.gov/diabetes/data/statistics-report/index.html. Reviewed January 18, 2022; Accessed: January 28, 2022.
Tucker ME. More Than 1 in 10 People in US Have Diabetes, CDC Says. Medscape Medical News. 2022 Jan 26. [Full Text].
Andes LJ, Cheng YJ, Rolka DB, Gregg EW, Imperatore G. Prevalence of Prediabetes Among Adolescents and Young Adults in the United States, 2005-2016. JAMA Pediatr. 2019 Dec 2. e194498. [QxMD MEDLINE Link]. [Full Text].
Dunleavy BP. Prevalence of prediabetes high among U.S. teens, young adults. 2019 Dec 2. Available at https://www.upi.com/Health_News/2019/12/02/Prevalence-of-prediabetes-high-among-US-teens-young-adults/8591575297926/.
Searing L. Over a quarter of 12-to-19-year-olds have prediabetes, research shows. The Washington Post. Available at https://www.washingtonpost.com/health/2022/04/05/prediabetes-youth/. April 5, 2022; Accessed: April 6, 2022.
Liu J, Li Y, Zhang D, Yi SS, Liu J. Trends in Prediabetes Among Youths in the US From 1999 Through 2018. JAMA Pediatr. 2022 Mar 28. [QxMD MEDLINE Link].
Hackethal V. 2 in 5 American Adults Will Develop Diabetes. Medscape Medical News. Available at http://www.medscape.com/viewarticle/829833. Accessed: August 13, 2014.
Gregg EW, Zhuo X, Albright AL, et al. Trends in lifetime risk and years of life lost due to diabetes in the USA, 1985—2011: a modelling study. The Lancet Diabetes & Endocrinology. Available at http://www.thelancet.com/journals/landia/article/PIIS2213-8587(14)70161-5/fulltext. Accessed: August 13, 2014.
Ludwig J, Sanbonmatsu L, Gennetian L, Adam E, Duncan GJ, Katz LF, et al. Neighborhoods, obesity, and diabetes--a randomized social experiment. N Engl J Med. 2011 Oct 20. 365(16):1509-19. [QxMD MEDLINE Link].
Tucker ME. IDF Atlas: 1 in 10 Adults Worldwide Now Has Diabetes. Medscape Medical News. 2021 Dec 7. [Full Text].
Selvin E, Steffes MW, Ballantyne CM, Hoogeveen RC, Coresh J, Brancati FL. Racial differences in glycemic markers: a cross-sectional analysis of community-based data. Ann Intern Med. 2011 Mar 1. 154(5):303-9. [QxMD MEDLINE Link]. [Full Text].
Albers JW, Herman WH, Pop-Busui R, Feldman EL, Martin CL, Cleary PA, et al. Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care. 2010 May. 33(5):1090-6. [QxMD MEDLINE Link]. [Full Text].
White NH, Sun W, Cleary PA, Tamborlane WV, Danis RP, Hainsworth DP, et al. Effect of prior intensive therapy in type 1 diabetes on 10-year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents. Diabetes. 2010 May. 59(5):1244-53. [QxMD MEDLINE Link]. [Full Text].
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998 Sep 12. 352(9131):837-53. [QxMD MEDLINE Link].
Perreault L, Pan Q, Mather KJ, Watson KE, Hamman RF, Kahn SE. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet. 2012 Jun 16. 379(9833):2243-51. [QxMD MEDLINE Link].
Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008 Oct 9. 359(15):1577-89. [QxMD MEDLINE Link].
Dluhy RG, McMahon GT. Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med. 2008 Jun 12. 358(24):2630-3. [QxMD MEDLINE Link].
Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol. 2009 Jan 20. 53(3):298-304. [QxMD MEDLINE Link].
Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009 Jan 8. 360(2):129-39. [QxMD MEDLINE Link].
Griffin SJ, Borch-Johnsen K, Davies MJ, Khunti K, Rutten GE, Sandbek A, et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet. 2011 Jul 9. 378(9786):156-67. [QxMD MEDLINE Link]. [Full Text].
Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008 Feb 7. 358(6):580-91. [QxMD MEDLINE Link].
Kerr D, Partridge H, Knott J, Thomas PW. HbA1c 3 months after diagnosis predicts premature mortality in patients with new onset type 2 diabetes. Diabet Med. 2011 Dec. 28(12):1520-4. [QxMD MEDLINE Link].
Gruss C, Gutierrez C, Burhans WC, DePamphilis ML, Koller T, Sogo JM. Nucleosome assembly in mammalian cell extracts before and after DNA replication. EMBO J. 1990 Sep. 9(9):2911-22. [QxMD MEDLINE Link]. [Full Text].
Zheng F, Yan L, Yang Z, Zhong B, Xie W. HbA_1c, diabetes and cognitive decline: the English Longitudinal Study of Ageing. Diabetologia. 2018 Jan 25. [QxMD MEDLINE Link]. [Full Text].
Melville NA. HbA1c Levels in Diabetes Linked to Cognitive Decline. Medscape Medical News. 2018 Jan 30. [Full Text].
Cano JF, Baena-Diez JM, Franch J, Vila J, Tello S, Sala J, et al. Long-term cardiovascular risk in type 2 diabetic compared with nondiabetic first acute myocardial infarction patients: a population-based cohort study in southern Europe. Diabetes Care. 2010 Sep. 33(9):2004-9. [QxMD MEDLINE Link]. [Full Text].
Yamasaki Y, Nakajima K, Kusuoka H, Izumi T, Kashiwagi A, Kawamori R, et al. Prognostic value of gated myocardial perfusion imaging for asymptomatic patients with type 2 diabetes: the J-ACCESS 2 investigation. Diabetes Care. 2010 Nov. 33(11):2320-6. [QxMD MEDLINE Link]. [Full Text].
Young LH, Wackers FJ, Chyun DA, Davey JA, Barrett EJ, Taillefer R, et al. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. JAMA. 2009 Apr 15. 301(15):1547-55. [QxMD MEDLINE Link]. [Full Text].
Murthy VL, Naya M, Foster CR, Gaber M, Hainer J, Klein J, et al. Association Between Coronary Vascular Dysfunction and Cardiac Mortality in Patients with and without Diabetes Mellitus. Circulation. 2012 Aug 23. [QxMD MEDLINE Link].
U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2011. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Available at http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf. Accessed: January 5, 2012.
National Institute of Diabetes and Digestive and Kidney Diseases. National Diabetes Statistics, 2011. National Diabetes Information Clearinghouse. Available at http://diabetes.niddk.nih.gov/dm/pubs/statistics/. Accessed: January 5, 2012.
Wannamethee SG, Shaper AG, Whincup PH, Lennon L, Sattar N. Impact of diabetes on cardiovascular disease risk and all-cause mortality in older men: influence of age at onset, diabetes duration, and established and novel risk factors. Arch Intern Med. 2011 Mar 14. 171(5):404-10. [QxMD MEDLINE Link].
Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011 Mar 3. 364(9):829-41. [QxMD MEDLINE Link].
Lind M, Olsson M, Rosengren A, Svensson AM, Bounias I, Gudbjornsdottir S. The relationship between glycaemic control and heart failure in 83,021 patients with type 2 diabetes. Diabetologia. 2012 Aug 16. [QxMD MEDLINE Link].
Shah AS, Khoury PR, Dolan LM, Ippisch HM, Urbina EM, Daniels SR, et al. The effects of obesity and type 2 diabetes mellitus on cardiac structure and function in adolescents and young adults. Diabetologia. 2011 Apr. 54(4):722-30. [QxMD MEDLINE Link].
Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, et al. Diabetes and cancer: a consensus report. Diabetes Care. 2010 Jul. 33(7):1674-85. [QxMD MEDLINE Link]. [Full Text].
Tseng CH. Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan. Diabetologia. 2011 Aug. 54(8):2009-15. [QxMD MEDLINE Link].
Colmers IN, Bowker SL, Majumdar SR, Johnson JA. Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis. CMAJ. 2012 Jul 3. [QxMD MEDLINE Link].
Yin M, Zhou J, Gorak EJ, Quddus F. Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: a systematic review and meta-analysis. Oncologist. 2013 Nov 20. [QxMD MEDLINE Link]. [Full Text].
Nelson R. Metformin boosts survival in diabetic cancer patients. Medscape Medical News. November 25, 2013. [Full Text].
Lopez-de-Andres A, Perez-Farinos N, de Miguel-Diez J, et al. Type 2 diabetes and postoperative pneumonia: An observational, population-based study using the Spanish Hospital Discharge Database, 2001-2015. PLoS One. 2019. 14 (2):e0211230. [QxMD MEDLINE Link]. [Full Text].
Chen Y, Yang D, Cheng B, et al. Clinical Characteristics and Outcomes of Patients With Diabetes and COVID-19 in Association With Glucose-Lowering Medication. Diabetes Care. 2020 May 14. [QxMD MEDLINE Link]. [Full Text].
Tucker ME. 'The Story Unfolding Is Worrisome' for Diabetes and COVID-19. Medscape Medical News. 2020 May 26. [Full Text].
Bode B, Garrett V, Messler J, et al. Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalized in the United States. J Diabetes Sci Technol. 2020. [Full Text].
Tucker ME. Pay Attention to In-Hospital Glucose to Save Lives in COVID-19. Medscape Medical News. 2020 Apr 20. [Full Text].
Barron E, Bakhai C, Kar P, et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. Lancet Diabetes Endocrinol. 2020 Aug 13. [QxMD MEDLINE Link]. [Full Text].
Tucker ME. Newly Published Articles Inform on COVID-19 Risk by Diabetes Type. Medscape Medical News. 2020 Aug 17. [Full Text].
Zhu L, She ZG, Cheng X, et al. Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes. Cell Metab. 2020 May 1. [QxMD MEDLINE Link]. [Full Text].
Tucker ME. Largest Study to Date Links Glucose Control to COVID-19 Outcomes. Medscape Medical News. 2020 May 14. [Full Text].
Holman N, Knighton P, Kar P, et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. Lancet Diabetes Endocrinol. 2020 Aug 13. [QxMD MEDLINE Link]. [Full Text].
Busko M. Older, Sicker Diabetes Patients Have Worse COVID-19 Prognosis. Medscape Medical News. 2021 Apr 28. [Full Text].
Schlesinger S, Neuenschwander M, Lang A, et al. Risk phenotypes of diabetes and association with COVID-19 severity and death: a living systematic review and meta-analysis. Diabetologia. 2021 Apr 28. [QxMD MEDLINE Link]. [Full Text].
Wang S, Ma P, Zhang S, et al. Fasting blood glucose at admission is an independent predictor for 28-day mortality in patients with COVID-19 without previous diagnosis of diabetes: a multi-centre retrospective study. Diabetologia. 2020 Jul 10. [QxMD MEDLINE Link]. [Full Text].
Tucker ME. Hyperglycemia predicts COVID-19 death even without diabetes. MDedge Internal Medicine. 2020 Jul 13. [Full Text].
Wang W, Shen M, Tao Y, et al. Elevated glucose level leads to rapid COVID-19 progression and high fatality. BMC Pulm Med. 2021 Feb 24. 21 (1):64. [QxMD MEDLINE Link]. [Full Text].
Carrasco-Sanchez FJ, Lopez-Carmona MD, Martinez-Marcos FJ, et al. Admission hyperglycaemia as a predictor of mortality in patients hospitalized with COVID-19 regardless of diabetes status: data from the Spanish SEMI-COVID-19 Registry. Ann Med. 2021 Dec. 53 (1):103-16. [QxMD MEDLINE Link].
Tucker ME. Blood Glucose on Admission Predicts COVID-19 Severity in All. Medscape Medical News. 2020 Nov 30. [Full Text].
Klonoff DC, Messler JC, Umpierrez GE, et al. Association Between Achieving Inpatient Glycemic Control and Clinical Outcomes in Hospitalized Patients With COVID-19: A Multicenter, Retrospective Hospital-Based Analysis. Diabetes Care. 2020 Dec 15. [QxMD MEDLINE Link]. [Full Text].
Harding A. Glycemia in Early COVID-19 Hospitalization Linked to Mortality. Reuters Health Information. 2020 Dec 21. [Full Text].
Sardu C, D'Onofrio N, Balestrieri ML, et al. Outcomes in Patients With Hyperglycemia Affected by Covid-19: Can We Do More on Glycemic Control?. Diabetes Care. 2020 May 19. [QxMD MEDLINE Link]. [Full Text].
Cariou B, Hadjadj S, Wargny M, et al. Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia. 2020 May 29. [QxMD MEDLINE Link]. [Full Text].
Tucker ME. 10% With Diabetes Hospitalized for COVID-19 Die Within a Week. Medscape Medical News. 2020 Jun 1. [Full Text].
Wargny M, Potier L, Gourdy P, et al. Predictors of hospital discharge and mortality in patients with diabetes and COVID-19: updated results from the nationwide CORONADO study. Diabetologia. 2021 Feb 17. [QxMD MEDLINE Link]. [Full Text].
Davenport L. 1 in 5 Diabetes Patients Hospitalized With COVID-19 Die in 28 Days. Medscape Medical News. 18 Feb 2021. [Full Text].
Centers for Disease Control and Prevention. Coronavirus Disease 2019 (COVID-19): People of Any Age with Underlying Medical Conditions. CDC. Available at https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html. Updated June 25, 2020; Accessed: June 27, 2020.
Murphy HR, Steel SA, Roland JM, Morris D, Ball V, Campbell PJ, et al. Obstetric and perinatal outcomes in pregnancies complicated by Type 1 and Type 2 diabetes: influences of glycaemic control, obesity and social disadvantage. Diabet Med. 2011 Sep. 28(9):1060-7. [QxMD MEDLINE Link]. [Full Text].
Sperl-Hillen J, Beaton S, Fernandes O, Von Worley A, Vazquez-Benitez G, Parker E, et al. Comparative effectiveness of patient education methods for type 2 diabetes: a randomized controlled trial. Arch Intern Med. 2011 Dec 12. 171(22):2001-10. [QxMD MEDLINE Link].
Khunti K, Gray LJ, Skinner T, Carey ME, Realf K, Dallosso H, et al. Effectiveness of a diabetes education and self management programme (DESMOND) for people with newly diagnosed type 2 diabetes mellitus: three year follow-up of a cluster randomised controlled trial in primary care. BMJ. 2012 Apr 26. 344:e2333. [QxMD MEDLINE Link]. [Full Text].
Duke SA, Colagiuri S, Colagiuri R. Individual patient education for people with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2009 Jan 21. CD005268. [QxMD MEDLINE Link].
Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care. 1992 Jul. 15(7):815-9. [QxMD MEDLINE Link].
Nainggolan L. Dawn Phenomenon Affects Half of Type 2 Diabetes Patients. Medscape Medical News. Nov 7 2013. [Full Text].
Monnier L, Colette C, Dejager S, et al. Magnitude of the dawn phenomenon and its impact on the overall glucose exposure in type 2 diabetes: is this of concern?. Diabetes Care. 2013 Oct 29. [QxMD MEDLINE Link].
Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: a systematic review. JAMA. 2007 Aug 22. 298(8):902-16. [QxMD MEDLINE Link].
Frank RN. Diabetic retinopathy. N Engl J Med. 2004 Jan 1. 350(1):48-58. [QxMD MEDLINE Link].
Ding J, Strachan MW, Fowkes FG, Wong TY, Macgillivray TJ, Patton N, et al. Association of retinal arteriolar dilatation with lower verbal memory: the Edinburgh Type 2 Diabetes Study. Diabetologia. 2011 Jul. 54(7):1653-62. [QxMD MEDLINE Link].
Hujoel PP, Stott-Miller M. Retinal and gingival hemorrhaging and chronic hyperglycemia. Diabetes Care. 2011 Jan. 34(1):181-3. [QxMD MEDLINE Link]. [Full Text].
[Guideline] American Association of Clinical Endocrinologists Statement on the Use of A1C for the Diagnosis of Diabetes. Available at https://www.aace.com/files/AACEpositionA1cfeb2010.pdf. Accessed: May 14 2012.
World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation. World Health Organization, Geneva, 2006. Available at http://whqlibdoc.who.int/publications/2006/9241594934_eng.pdf.
Brambilla P, La Valle E, Falbo R, Limonta G, Signorini S, Cappellini F, et al. Normal fasting plasma glucose and risk of type 2 diabetes. Diabetes Care. 2011 Jun. 34(6):1372-4. [QxMD MEDLINE Link]. [Full Text].
[Guideline] Sacks DB, Arnold M, Bakris GL, Bruns DE, Horvath AR, Kirkman MS, et al. Executive summary: guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem. 2011 Jun. 57(6):793-8. [QxMD MEDLINE Link].
International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 2009 Jul. 32(7):1327-34. [QxMD MEDLINE Link]. [Full Text].
Huang ES, Liu JY, Moffet HH, John PM, Karter AJ. Glycemic control, complications, and death in older diabetic patients: the diabetes and aging study. Diabetes Care. 2011 Jun. 34(6):1329-36. [QxMD MEDLINE Link]. [Full Text].
Wang W, Lee ET, Howard BV, Fabsitz RR, Devereux RB, Welty TK. Fasting plasma glucose and hemoglobin A1c in identifying and predicting diabetes: the strong heart study. Diabetes Care. 2011 Feb. 34(2):363-8. [QxMD MEDLINE Link]. [Full Text].
Brooks M. Hemoglobin A1c misses many cases of diabetes. Medscape. 2019 Mar 28. [Full Text].
Nowicka P, Santoro N, Liu H, Lartaud D, Shaw MM, Goldberg R, et al. Utility of hemoglobin A(1c) for diagnosing prediabetes and diabetes in obese children and adolescents. Diabetes Care. 2011 Jun. 34(6):1306-11. [QxMD MEDLINE Link]. [Full Text].
Vijayakumar P, Nelson RG, Hanson RL, Knowler WC, Sinha M. HbA1c and the Prediction of Type 2 Diabetes in Children and Adults. Diabetes Care. 2017 Jan. 40 (1):16-21. [QxMD MEDLINE Link]. [Full Text].
Davenport L. HbA1c Predicts Diabetes Risk in Children and Adolescents. Medscape Medical News. 2017 Jan 4. [Full Text].
Lu ZX, Walker KZ, O'Dea K, Sikaris KA, Shaw JE. A1C for screening and diagnosis of type 2 diabetes in routine clinical practice. Diabetes Care. 2010 Apr. 33(4):817-9. [QxMD MEDLINE Link]. [Full Text].
Lerner N, Shani M, Vinker S. Predicting type 2 diabetes mellitus using haemoglobin A1c: A community-based historic cohort study. Eur J Gen Pract. 2013 Nov 29. [QxMD MEDLINE Link].
McCall B. Simple saliva swab and early HbA1c test predict diabetes. Medscape Medical News. February 11, 2014. [Full Text].
Gerstein HC, Islam S, Anand S, Almahmeed W, Damasceno A, Dans A, et al. Dysglycaemia and the risk of acute myocardial infarction in multiple ethnic groups: an analysis of 15,780 patients from the INTERHEART study. Diabetologia. 2010 Dec. 53(12):2509-17. [QxMD MEDLINE Link].
Suzuki S, Koga M, Amamiya S, Nakao A, Wada K, Okuhara K, et al. Glycated albumin but not HbA1c reflects glycaemic control in patients with neonatal diabetes mellitus. Diabetologia. 2011 Sep. 54(9):2247-53. [QxMD MEDLINE Link].
Wilson DM, Xing D, Cheng J, Beck RW, Hirsch I, Kollman C, et al. Persistence of individual variations in glycated hemoglobin: analysis of data from the Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Randomized Trial. Diabetes Care. 2011 Jun. 34(6):1315-7. [QxMD MEDLINE Link]. [Full Text].
American Diabetes Association. Standards of Medical Care in Diabetes-2015: Abridged for Primary Care Providers. Clinical Diabetes. 2015. 33(2):[Full Text].
Colayco DC, Niu F, McCombs JS, Cheetham TC. A1C and cardiovascular outcomes in type 2 diabetes: a nested case-control study. Diabetes Care. 2011 Jan. 34(1):77-83. [QxMD MEDLINE Link]. [Full Text].
Gerstein HC, Miller ME, Genuth S, Ismail-Beigi F, Buse JB, Goff DC Jr, et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med. 2011 Mar 3. 364(9):818-28. [QxMD MEDLINE Link].
Ng JM, Cooke M, Bhandari S, Atkin SL, Kilpatrick ES. The effect of iron and erythropoietin treatment on the A1C of patients with diabetes and chronic kidney disease. Diabetes Care. 2010 Nov. 33(11):2310-3. [QxMD MEDLINE Link]. [Full Text].
Morrison F, Shubina M, Turchin A. Encounter frequency and serum glucose level, blood pressure, and cholesterol level control in patients with diabetes mellitus. Arch Intern Med. 2011 Sep 26. 171(17):1542-50. [QxMD MEDLINE Link].
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998 Sep 12. 352(9131):854-65. [QxMD MEDLINE Link].
[Guideline] Busko M. HbA1c Below 8% in Diabetes for 'Most' Says ACP, But Others Disagree. Medscape Medical News. 2018 Mar 5. [Full Text].
[Guideline] Qaseem A, Wilt TJ, Kansagara D, et al. Hemoglobin A1c Targets for Glycemic Control With Pharmacologic Therapy for Nonpregnant Adults With Type 2 Diabetes Mellitus: A Guidance Statement Update From the American College of Physicians. Ann Intern Med. 2018 Mar 6. [QxMD MEDLINE Link]. [Full Text].
Tucker ME. Type 2 Diabetes 'Remission' Is a Reality, Say Major Organizations. Medscape Medical News. 2021 Sep 1. [Full Text].
Riddle MC, Cefalu WT, Evans PH, et al. Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes. J Clin Endocrinol Metab. 2021 Aug 30. [QxMD MEDLINE Link]. [Full Text].
Alfayez OM, Al Yami MS, Alshibani M, et al. Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs. Prim Care Diabetes. 2019 Jan 31. [QxMD MEDLINE Link].
Scarpello JH, Howlett HC. Metformin therapy and clinical uses. Diab Vasc Dis Res. 2008 Sep. 5(3):157-67. [QxMD MEDLINE Link].
Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR. Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis. Diabetes Care. 2008 Nov. 31(11):2086-91. [QxMD MEDLINE Link]. [Full Text].
Sun L, Xie C, Wang G, et al. Gut microbiota and intestinal FXR mediate the clinical benefits of metformin. Nat Med. 2018 Dec. 24 (12):1919-29. [QxMD MEDLINE Link].
Melville NA. Metformin's Effect in Diabetes Linked to Gut Microbiota Changes. Medscape Medical News. 2018 Nov 29. [Full Text].
Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999 Jun 2. 281(21):2005-12. [QxMD MEDLINE Link].
UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. U.K. Prospective Diabetes Study Group. Diabetes Care. 1998 Jan. 21(1):87-92. [QxMD MEDLINE Link].
Qaseem A, Barry MJ, Humphrey LL, Forciea MA, Clinical Guidelines Committee of the American College of Physicians. Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline Update From the American College of Physicians. Ann Intern Med. 2017 Jan 3. [QxMD MEDLINE Link]. [Full Text].
Tucker ME. ACP Updates Guidelines for Type 2 Diabetes Care. Medscape Medical News. 2017 Jan 3. [Full Text].
Vashisht R, Jung K, Schuler A, et al. Association of Hemoglobin A1c Levels With Use of Sulfonylureas, Dipeptidyl Peptidase 4 Inhibitors, and Thiazolidinediones in Patients With Type 2 Diabetes Treated With Metformin: Analysis From the Observational Health Data Sciences and Informatics Initiative. JAMA Net Open. 2018 Aug 24. 1(4):[Full Text].
Tucker ME. Big Data Confirm Type 2 Diabetes Treatment Approach. Medscape Medical News. 2018 Aug 31. [Full Text].
Kooy A, de Jager J, Lehert P, Bets D, Wulffele MG, Donker AJ, et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med. 2009 Mar 23. 169(6):616-25. [QxMD MEDLINE Link].
Pradhan AD, Everett BM, Cook NR, Rifai N, Ridker PM. Effects of initiating insulin and metformin on glycemic control and inflammatory biomarkers among patients with type 2 diabetes: the LANCET randomized trial. JAMA. 2009 Sep 16. 302(11):1186-94. [QxMD MEDLINE Link].
Andersson C, Olesen JB, Hansen PR, Weeke P, Norgaard ML, Jorgensen CH, et al. Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: a retrospective nationwide cohort study. Diabetologia. 2010 Dec. 53(12):2546-53. [QxMD MEDLINE Link].
Roussel R, Travert F, Pasquet B, Wilson PW, Smith SC Jr, Goto S, et al. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med. 2010 Nov 22. 170(21):1892-9. [QxMD MEDLINE Link].
Gross JL, Kramer CK, Leitão CB, Hawkins N, Viana LV, Schaan BD, et al. Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis. Ann Intern Med. 2011 May 17. 154(10):672-9. [QxMD MEDLINE Link].
Zeller M, Danchin N, Simon D, Vahanian A, Lorgis L, Cottin Y, et al. Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction. J Clin Endocrinol Metab. 2010 Nov. 95(11):4993-5002. [QxMD MEDLINE Link].
Bellomo Damato A, Stefanelli G, Laviola L, Giorgino R, Giorgino F. Nateglinide provides tighter glycaemic control than glyburide in patients with Type 2 diabetes with prevalent postprandial hyperglycaemia. Diabet Med. 2011 May. 28(5):560-6. [QxMD MEDLINE Link].
Retnakaran R, Qi Y, Harris SB, Hanley AJ, Zinman B. Changes over time in glycemic control, insulin sensitivity, and beta-cell function in response to low-dose metformin and thiazolidinedione combination therapy in patients with impaired glucose tolerance. Diabetes Care. 2011 Jul. 34(7):1601-4. [QxMD MEDLINE Link]. [Full Text].
DeFronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med. 2011 Mar 24. 364(12):1104-15. [QxMD MEDLINE Link].
Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006 Sep 23. 368(9541):1096-105. [QxMD MEDLINE Link].
Phung OJ, Sood NA, Sill BE, Coleman CI. Oral anti-diabetic drugs for the prevention of Type 2 diabetes. Diabet Med. 2011 Aug. 28(8):948-64. [QxMD MEDLINE Link].
Charpentier G, Halimi S. Earlier triple therapy with pioglitazone in patients with type 2 diabetes. Diabetes Obes Metab. 2009 Sep. 11(9):844-54. [QxMD MEDLINE Link].
Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005 Oct 8. 366(9493):1279-89. [QxMD MEDLINE Link].
Rennings AJ, Russel FG, Li Y, Deen PM, Masereeuw R, Tack CJ, et al. Preserved response to diuretics in rosiglitazone-treated subjects with insulin resistance: a randomized double-blind placebo-controlled crossover study. Clin Pharmacol Ther. 2011 Apr. 89(4):587-94. [QxMD MEDLINE Link].
Lewis JD, Ferrara A, Peng T, Hedderson M, Bilker WB, Quesenberry CP Jr, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care. 2011 Apr. 34(4):916-22. [QxMD MEDLINE Link]. [Full Text].
Ferrara A, Lewis JD, Quesenberry CP Jr, Peng T, Strom BL, Van Den Eeden SK, et al. Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care. 2011 Apr. 34(4):923-9. [QxMD MEDLINE Link]. [Full Text].
Piccinni C, Motola D, Marchesini G, Poluzzi E. Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care. 2011 Jun. 34(6):1369-71. [QxMD MEDLINE Link]. [Full Text].
Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ. 2009 Jan 6. 180(1):32-9. [QxMD MEDLINE Link]. [Full Text].
US Food and Drug Administration. FDA Drug Safety Communication: Updated Risk Evaluation and Mitigation Strategy (REMS) to Restrict Access to Rosiglitazone-containing Medicines including Avandia, Avandamet, and Avandaryl. Available at http://www.fda.gov/Drugs/DrugSafety/ucm255005.htm. Accessed: January 20, 2012.
Bunck MC, Diamant M, Corner A, Eliasson B, Malloy JL, Shaginian RM, et al. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care. 2009 May. 32(5):762-8. [QxMD MEDLINE Link]. [Full Text].
Buse JB, Bergenstal RM, Glass LC, Heilmann CR, Lewis MS, Kwan AY, et al. Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med. 2011 Jan 18. 154(2):103-12. [QxMD MEDLINE Link].
Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008 Oct 4. 372(9645):1240-50. [QxMD MEDLINE Link].
Pencek R, Blickensderfer A, Li Y, Brunell SC, Chen S. Exenatide once weekly for the treatment of type 2 diabetes: effectiveness and tolerability in patient subpopulations. Int J Clin Pract. 2012 Aug 24. [QxMD MEDLINE Link].
Blevins T, Pullman J, Malloy J, Yan P, Taylor K, Schulteis C, et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011 May. 96(5):1301-10. [QxMD MEDLINE Link].
Douglas D. Exenatide More Effective Than Insulin Detemir: Study. Available at http://www.medscape.com/viewarticle/777411. Accessed: January 15, 2013.
Davies M, Heller S, Sreenan S, Sapin H, Adetunji O, Tahbaz A, et al. Once-Weekly Exenatide Versus Once- or Twice-Daily Insulin Detemir: Randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas. Diabetes Care. 2012 Dec 28. [QxMD MEDLINE Link].
Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016 Jul 28. 375 (4):311-22. [QxMD MEDLINE Link]. [Full Text].
Tamborlane WV, Barrientos-Perez M, Fainberg U, et al. Liraglutide in Children and Adolescents with Type 2 Diabetes. N Engl J Med. 2019 Apr 28. [QxMD MEDLINE Link].
US Food and Drug Administration. FDA approves Tanzeum to treat type 2 diabetes [press release]. April 15, 2014. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm393289.htm. Accessed: April 21, 2014.
Busko M. FDA approves weekly injectable diabetes drug: albiglutide. Medscape Medical News. April 15, 2014. [Full Text].
Douglas D. Albiglutide Long-Acting Option for Diabetes Control. Medscape Medical News. Available at http://www.medscape.com/viewarticle/821700. Accessed: March 17, 2014.
Pratley RE, Nauck MA, Barnett AH, et al. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes Endocrinol. 2014. Feb 6. [Epub ahead of print].
Tucker M. FDA Approves Once-Weekly Dulaglutide for Type 2 Diabetes. Medscape Medical News. Available at http://www.medscape.com/viewarticle/831969. Accessed: September 26, 2014.
Wysham C, Blevins T, Arakaki R, Colon G, Garcia P, Atisso C, et al. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care. 2014 Aug. 37(8):2159-67. [QxMD MEDLINE Link].
Frias JP, Bonora E, Nevarez Ruiz LA, et al. Efficacy and Safety of Dulaglutide 3mg and 4.5mg vs. Dulaglutide 1.5mg: 52-Week Results from AWARD-11 (Abst 357-OR). Presented at the 80th Scientific sessions American of the Diabetes Association. 2020 Jun 12-16. Chicago, IL. Available at https://diabetes.diabetesjournals.org/content/69/Supplement_1/357-OR.
Umpierrez G, Tofe Povedano S, Perez Manghi F, Shurzinske L, Pechtner V. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care. 2014 Aug. 37(8):2168-76. [QxMD MEDLINE Link].
Nauck M, Weinstock RS, Umpierrez GE, Guerci B, Skrivanek Z, Milicevic Z. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care. 2014 Aug. 37(8):2149-58. [QxMD MEDLINE Link]. [Full Text].
Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019 Jul 13. 394 (10193):121-30. [QxMD MEDLINE Link].
Ahren B, Galstyan G, Gautier JF, et al. Postprandial Glucagon Reductions Correlate to Reductions in Postprandial Glucose and Glycated Hemoglobin with Lixisenatide Treatment in Type 2 Diabetes Mellitus: A Post Hoc Analysis. Diabetes Ther. 2016 Jun 18. [QxMD MEDLINE Link].
Yabe D, Ambos A, Cariou B, et al. Efficacy of lixisenatide in patients with type 2 diabetes: A post hoc analysis of patients with diverse β-cell function in the GetGoal-M and GetGoal-S trials. J Diabetes Complications. 2016 May 24. [QxMD MEDLINE Link]. [Full Text].
Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med. 2015 Dec 3. 373 (23):2247-57. [QxMD MEDLINE Link]. [Full Text].
Fonseca VA, Alvarado-Ruiz R, Raccah D, Boka G, Miossec P, Gerich JE. Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono). Diabetes Care. 2012 Jun. 35(6):1225-31. [QxMD MEDLINE Link]. [Full Text].
Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016 Nov 10. 375 (19):1834-44. [QxMD MEDLINE Link]. [Full Text].
Tucker ME. FDA Approves CVD Benefit for Once-Weekly Semaglutide. Medscape Medical News. 2020 Jan 17. [Full Text].
Ozempic (semaglutide SC) [package insert]. Plainsboro, NJ: Novo Nordisk. January 2020. Available at [Full Text].
Rosenstock J, Allison D, Birkenfeld AL, et al. Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial. JAMA. 2019 Apr 16. 321 (15):1466-80. [QxMD MEDLINE Link]. [Full Text].
Rodbard HW, Rosenstock J, Canani LH, et al. Oral Semaglutide versus Empagliflozin in Patients with Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial. Diabetes Care. 2019 Sep 17. [QxMD MEDLINE Link].
Pratley R, Amod A, Hoff ST, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet. 2019 Jul 6. 394 (10192):39-50. [QxMD MEDLINE Link].
Rybelsus (semaglutide oral) [package insert]. Plainsboro, NJ: Novo Nordisk. January 2020. Available at [Full Text].
Frías JP, Davies MJ, Rosenstock J, and the, SURPASS-2 Investigators. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021 Aug 5. 385 (6):503-515. [QxMD MEDLINE Link]. [Full Text].
Aschner P, Katzeff HL, Guo H, Sunga S, Williams-Herman D, Kaufman KD, et al. Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. Diabetes Obes Metab. 2010 Mar. 12(3):252-61. [QxMD MEDLINE Link].
Vilsboll T, Rosenstock J, Yki-Jarvinen H, Cefalu WT, Chen Y, Luo E, et al. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2010 Feb. 12(2):167-77. [QxMD MEDLINE Link].
Perez-Monteverde A, Seck T, Xu L, Lee MA, Sisk CM, Williams-Herman DE, et al. Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naïve patients with type 2 diabetes. Int J Clin Pract. 2011 Sep. 65(9):930-8. [QxMD MEDLINE Link].
Owens DR, Swallow R, Dugi KA, Woerle HJ. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study. Diabet Med. 2011 Nov. 28(11):1352-61. [QxMD MEDLINE Link].
Willemen MJ, Mantel-Teeuwisse AK, Straus SM, Meyboom RH, Egberts TC, Leufkens HG. Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase. Diabetes Care. 2011 Feb. 34(2):369-74. [QxMD MEDLINE Link]. [Full Text].
Monami M, Dicembrini I, Antenore A, Mannucci E. Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials. Diabetes Care. 2011 Nov. 34(11):2474-6. [QxMD MEDLINE Link]. [Full Text].
Solerte SB, D'Addio F, Trevisan R, et al. Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study. Diabetes Care. 2020 Sep 29. [QxMD MEDLINE Link]. [Full Text].
Zoler ML. Fewer Deaths in Hospitalized COVID Diabetes Patients on Sitagliptin. Medscape Medical News. 2020 Oct 1. [Full Text].
Nainggolan L. FDA approves canagliflozin, a first-in-class diabetes drug. March 29, 2013. Medscape Medical News. Available at http://www.medscape.com/viewarticle/781709. Accessed: April 2, 2013.
US Food and Drug Administration. FDA approves Invokana to treat type 2 diabetes [press release]. March 29, 2013. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm345848.htm. Accessed: April 2, 2013.
Tucker M. FDA Approves Dapagliflozin (Farxiga) for Type 2 Diabetes Treatment. Medscape Medical News. Available at http://www.medscape.com/viewarticle/818858. Accessed: January 13, 2014.
FDA News Release. FDA approves Farxiga to treat type 2 diabetes. U.S. Food and Drug Administration. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm380829.htm. Accessed: January 13, 2014.
Roden M, Weng J, Eilbracht J, et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2013 Nov. 1(3):208-19. [QxMD MEDLINE Link].
Ridderstrale M, Andersen KR, Zeller C, Kim G, Woerle HJ, Broedl UC. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol. 2014 Jun 16. [QxMD MEDLINE Link].
Stenlof K, Cefalu WT, Kim KA, Alba M, Usiskin K, Tong C, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013 Apr. 15(4):372-82. [QxMD MEDLINE Link]. [Full Text].
Clar C, Gill JA, Court R, Waugh N. Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open. 2012. 2(5):[QxMD MEDLINE Link]. [Full Text].
Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019 Jun 13. 380 (24):2295-306. [QxMD MEDLINE Link].
Wilding JP, Woo V, Soler NG, Pahor A, Sugg J, Rohwedder K, et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med. 2012 Mar 20. 156(6):405-15. [QxMD MEDLINE Link].
Nauck MA, Del Prato S, Meier JJ, Duran-Garcia S, Rohwedder K, Elze M, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011 Sep. 34(9):2015-22. [QxMD MEDLINE Link]. [Full Text].
Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2011 Oct. 13(10):928-38. [QxMD MEDLINE Link].
Rosenstock J, Vico M, Wei L, Salsali A, List JF. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care. 2012 Jul. 35(7):1473-8. [QxMD MEDLINE Link]. [Full Text].
Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019 Jan 24. 380 (4):347-57. [QxMD MEDLINE Link]. [Full Text].
Tucker ME. FDA Approves Empagliflozin for Reducing CVD Death. Medscape Medical News. 2016 Dec 2. [Full Text].
Peters AL. 'Incredibly Exciting': Diabetes Drug With CV Benefits. Medscape. 2016 Dec 21. [Full Text].
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015 Nov 26. 373 (22):2117-28. [QxMD MEDLINE Link]. [Full Text].
Terra SG, Focht K, Davies M, et al. Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone. Diabetes Obes Metab. 2017 May. 19 (5):721-8. [QxMD MEDLINE Link].
Rosenstock J, Frias J, Pall D, et al. Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET). Diabetes Obes Metab. 2017 Aug 31. [QxMD MEDLINE Link].
Dagogo-Jack S, Liu J, Eldor R, et al. Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study. Diabetes Obes Metab. 2017 Sep 17. [QxMD MEDLINE Link]. [Full Text].
Zoler ML. FDA Approves Finerenone (Kerendia) for Slowing CKD in Type 2 Diabetes. Medscape Medical News. 2021 Jul 12. [Full Text].
Bakris GL, Agarwal R, Anker SD, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020 Dec 3. 383 (23):2219-29. [QxMD MEDLINE Link]. [Full Text].
US Food and Drug Administration. FDA Approves Drug to Reduce Risk of Serious Kidney and Heart Complications in Adults with Chronic Kidney Disease Associated with Type 2 Diabetes. FDA. Available at https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-drug-reduce-risk-serious-kidney-and-heart-complications-adults-chronic-kidney-disease. July 9, 2021; Accessed: July 15, 2021.
de la Pena A, Riddle M, Morrow LA, Jiang HH, Linnebjerg H, Scott A, et al. Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjects. Diabetes Care. 2011 Dec. 34(12):2496-501. [QxMD MEDLINE Link]. [Full Text].
Agency for Healthcare Research and Quality. Comparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes. AHRQ: Agency for Healthcare Research and Quality. Available at http://www.effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-and-reports/?productid=108&pageaction=displayproduct.. Accessed: March 7, 2012.
Blair HA, Keating GM. Insulin Glargine 300 U/mL: A Review in Diabetes Mellitus. Drugs. 2016 Mar. 76 (3):363-74. [QxMD MEDLINE Link].
Toujeo. US Food and Drug Administration. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206538s006lbl.pdf. Accessed: 2018 Apr 25.
Davies MJ, Gross JL, Ono Y, Sasaki T, Bantwal G, Gall MA, et al. Efficacy and safety of insulin degludec given as part of basal-bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trial. Diabetes Obes Metab. 2014 Oct. 16 (10):922-30. [QxMD MEDLINE Link]. [Full Text].
Zinman B, DeVries JH, Bode B, Russell-Jones D, Leiter LA, Moses A, et al. Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials. Lancet Diabetes Endocrinol. 2013 Oct. 1 (2):123-31. [QxMD MEDLINE Link].
Zinman B, Fulcher G, Rao PV, Thomas N, Endahl LA, Johansen T, et al. Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. Lancet. 2011 Mar 12. 377(9769):924-31. [QxMD MEDLINE Link].
Afrezza (insulin inhaled) prescribing information [package insert]. Valencia CA, United States: MannKind Corporation. June 2014. Available at [Full Text].
Fiasp (insulin aspart) [package insert]. 800 Scudders Mill Road, Plainsboro, NJ 08536: Novo Nordisk Inc. September 2017. Available at [Full Text].
Nainggolan L. FDA Approves New Fast-Acting Insulin, Fiasp, for Diabetes in Adults. Medscape Medical News. 2017 Sep 29. [Full Text].
US Food and Drug Administration. Early Communication About Safety of Lantus (Insulin Glargine). [Full Text].
Suissa S, Azoulay L, Dell'Aniello S, Evans M, Vora J, Pollak M. Long-term effects of insulin glargine on the risk of breast cancer. Diabetologia. 2011 Sep. 54(9):2254-62. [QxMD MEDLINE Link].
Johnson JA, Bowker SL, Richardson K, Marra CA. Time-varying incidence of cancer after the onset of type 2 diabetes: evidence of potential detection bias. Diabetologia. 2011 Sep. 54(9):2263-71. [QxMD MEDLINE Link].
Stefansdottir G, Zoungas S, Chalmers J, Kengne AP, Knol MJ, Leufkens HG, et al. Intensive glucose control and risk of cancer in patients with type 2 diabetes. Diabetologia. 2011 Jul. 54(7):1608-14. [QxMD MEDLINE Link].
Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2011 Oct 5. CD006423. [QxMD MEDLINE Link].
Handelsman Y, Goldberg RB, Garvey WT, Fonseca VA, Rosenstock J, Jones MR, et al. Colesevelam hydrochloride to treat hypercholesterolemia and improve glycemia in prediabetes: a randomized, prospective study. Endocr Pract. 2010 Jul-Aug. 16(4):617-28. [QxMD MEDLINE Link].
Rosenstock J, Fonseca VA, Garvey WT, Goldberg RB, Handelsman Y, Abby SL, et al. Initial combination therapy with metformin and colesevelam for achievement of glycemic and lipid goals in early type 2 diabetes. Endocr Pract. 2010 Jul-Aug. 16(4):629-40. [QxMD MEDLINE Link].
Sando KR, Taylor J. Bromocriptine: its place in type 2 diabetes Tx. J Fam Pract. 2011 Nov. 60(11):E1-5. [QxMD MEDLINE Link].
Gaziano JM, Cincotta AH, O'Connor CM, Ezrokhi M, Rutty D, Ma ZJ, et al. Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. Diabetes Care. 2010 Jul. 33(7):1503-8. [QxMD MEDLINE Link]. [Full Text].
Bolen S, Wilson L, Vassy J, Feldman L, Yeh J, Marinopoulos S, et al. Undefined. 2007 Jul. [QxMD MEDLINE Link].
Bennett WL, Wilson LM, Bolen S, Maruthur N, Singh S, Chatterjee R, et al. Undefined. 2011 Mar. [QxMD MEDLINE Link].
Tucker ME. New AACE algorithm addresses all aspects of type 2 diabetes. Medscape Medical News. April 23, 2013. [Full Text].
[Guideline] Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al. AACE Comprehensive Diabetes Management Algorithm 2013. Endocr Pract. 2013 Mar-Apr. 19(2):327-36. [QxMD MEDLINE Link].
Boule NG, Robert C, Bell GJ, Johnson ST, Bell RC, Lewanczuk RZ, et al. Metformin and exercise in type 2 diabetes: examining treatment modality interactions. Diabetes Care. 2011 Jul. 34(7):1469-74. [QxMD MEDLINE Link]. [Full Text].
Brooks M. Metformin Cuts Dementia Risk in Type 2 Diabetes. Medscape Medical News. Available at http://www.medscape.com/viewarticle/807886. Accessed: July 23, 2013.
Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009 Sep-Oct. 15(6):540-59. [QxMD MEDLINE Link].
Qayyum R, Bolen S, Maruthur N, Feldman L, Wilson LM, Marinopoulos SS, et al. Systematic review: comparative effectiveness and safety of premixed insulin analogues in type 2 diabetes. Ann Intern Med. 2008 Oct 21. 149(8):549-59. [QxMD MEDLINE Link].
Porcellati F, Lucidi P, Rossetti P, Candeloro P, Andreoli AM, Marzotti S, et al. Differential effects of adiposity on pharmacodynamics of basal insulins NPH, glargine, and detemir in type 2 diabetes mellitus. Diabetes Care. 2011 Dec. 34(12):2521-3. [QxMD MEDLINE Link]. [Full Text].
Baldwin D, Zander J, Munoz C, Raghu P, Delange-Hudec S, Lee H, et al. A Randomized Trial of Two Weight-Based Doses of Insulin Glargine and Glulisine in Hospitalized Subjects With Type 2 Diabetes and Renal Insufficiency. Diabetes Care. 2012 Jun 14. [QxMD MEDLINE Link].
Grunberger G, Abelseth JM, Bailey TS, Bode BW, Handelsman Y, Hellman R. Consensus statement by the american association of clinical endocrinologists/american college of endocrinology insulin pump management task force. Endocr Pract. 2014 May 1. 20(5):463-89. [QxMD MEDLINE Link].
Fritsche A, Larbig M, Owens D, Haring HU. Comparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes-results of the GINGER study. Diabetes Obes Metab. 2010 Feb. 12(2):115-23. [QxMD MEDLINE Link].
Siegelaar SE, Kerr L, Jacober SJ, Devries JH. A decrease in glucose variability does not reduce cardiovascular event rates in type 2 diabetic patients after acute myocardial infarction: a reanalysis of the HEART2D study. Diabetes Care. 2011 Apr. 34(4):855-7. [QxMD MEDLINE Link]. [Full Text].
Chen MJ, Jovanovic A, Taylor R. Utilizing the second-meal effect in type 2 diabetes: practical use of a soya-yogurt snack. Diabetes Care. 2010 Dec. 33(12):2552-4. [QxMD MEDLINE Link]. [Full Text].
Qaseem A, Vijan S, Snow V, Cross JT, Weiss KB, Owens DK. Glycemic control and type 2 diabetes mellitus: the optimal hemoglobin A1c targets. A guidance statement from the American College of Physicians. Ann Intern Med. 2007 Sep 18. 147(6):417-22. [QxMD MEDLINE Link].
Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassaï B, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ. 2011 Jul 26. 343:d4169. [QxMD MEDLINE Link]. [Full Text].
Tucker ME. Diabetes in the Elderly Addressed in Consensus Report. Medscape Medical News. October 25, 2012. Accessed November 13, 2012.
Sue Kirkman M, Briscoe VJ, Clark N, et al. Diabetes in Older Adults: A Consensus Report. J Am Geriatr Soc. 2012 Oct 25. [QxMD MEDLINE Link].
Klonoff DC, Buckingham B, Christiansen JS, Montori VM, Tamborlane WV, Vigersky RA, et al. Continuous glucose monitoring: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2011 Oct. 96(10):2968-79. [QxMD MEDLINE Link].
Kompala T, Neinstein A. A new era: increasing continuous glucose monitoring use in type 2 diabetes. Am J Manag Care. 2019 Mar. 25 (4 Spec No.):SP123-6. [QxMD MEDLINE Link]. [Full Text].
Tucker ME. Noninvasive, Low Cost CGM for Type 2 Diabetes Coming in US and EU. Medscape Medical News. 2020 Dec 2. [Full Text].
Ahmedani MY, Ul Haque MS, Basit A, Fawwad A, Alvi SF. Ramadan Prospective Diabetes Study: the role of drug dosage and timing alteration, active glucose monitoring and patient education. Diabet Med. 2012 Jan 11. [QxMD MEDLINE Link].
Wing RR, Lang W, Wadden TA, Safford M, Knowler WC, Bertoni AG, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011 Jul. 34(7):1481-6. [QxMD MEDLINE Link]. [Full Text].
Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, Coday M, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013 Jul 11. 369(2):145-54. [QxMD MEDLINE Link]. [Full Text].
Lazo M, Solga SF, Horska A, Bonekamp S, Diehl AM, Brancati FL, et al. Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. Diabetes Care. 2010 Oct. 33(10):2156-63. [QxMD MEDLINE Link]. [Full Text].
Lean MEJ, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet. 2017 Dec 5. [Full Text].
Nainggolan L. Liquid Diet, Gradual Reintroduction of Food, Prompts Diabetes Remission. Medscape. 2017 Dec 5. [Full Text].
Esposito K, Maiorino MI, Ciotola M, Di Palo C, Scognamiglio P, Gicchino M, et al. Effects of a Mediterranean-style diet on the need for antihyperglycemic drug therapy in patients with newly diagnosed type 2 diabetes: a randomized trial. Ann Intern Med. 2009 Sep 1. 151(5):306-14. [QxMD MEDLINE Link].
Larsen RN, Mann NJ, Maclean E, Shaw JE. The effect of high-protein, low-carbohydrate diets in the treatment of type 2 diabetes: a 12 month randomised controlled trial. Diabetologia. 2011 Apr. 54(4):731-40. [QxMD MEDLINE Link].
Bassil M, Burgos S, Marliss EB, Morais JA, Chevalier S, Gougeon R. Hyperaminoacidaemia at postprandial levels does not modulate glucose metabolism in type 2 diabetes mellitus. Diabetologia. 2011 Jul. 54(7):1810-8. [QxMD MEDLINE Link].
Mozaffarian D, Cao H, King IB, Lemaitre RN, Song X, Siscovick DS, et al. Trans-palmitoleic acid, metabolic risk factors, and new-onset diabetes in U.S. adults: a cohort study. Ann Intern Med. 2010 Dec 21. 153(12):790-9. [QxMD MEDLINE Link]. [Full Text].
Uribarri J, Cai W, Ramdas M, Goodman S, Pyzik R, Chen X, et al. Restriction of advanced glycation end products improves insulin resistance in human type 2 diabetes: potential role of AGER1 and SIRT1. Diabetes Care. 2011 Jul. 34(7):1610-6. [QxMD MEDLINE Link]. [Full Text].
Reeds DN, Patterson BW, Okunade A, Holloszy JO, Polonsky KS, Klein S. Ginseng and ginsenoside Re do not improve ß-cell function or insulin sensitivity in overweight and obese subjects with impaired glucose tolerance or diabetes. Diabetes Care. 2011 May. 34(5):1071-6. [QxMD MEDLINE Link]. [Full Text].
Clerici C, Nardi E, Battezzati PM, Asciutti S, Castellani D, Corazzi N, et al. Novel soy germ pasta improves endothelial function, blood pressure, and oxidative stress in patients with type 2 diabetes. Diabetes Care. 2011 Sep. 34(9):1946-8. [QxMD MEDLINE Link]. [Full Text].
n-3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia. N Engl J Med. 2012 Jun 11. [QxMD MEDLINE Link].
Umpierre D, Ribeiro PA, Kramer CK, Leitao CB, Zucatti AT, Azevedo MJ, et al. Physical activity advice only or structured exercise training and association with HbA1c levels in type 2 diabetes: a systematic review and meta-analysis. JAMA. 2011 May 4. 305(17):1790-9. [QxMD MEDLINE Link].
Balducci S, Zanuso S, Nicolucci A, De Feo P, Cavallo S, Cardelli P, et al. Effect of an intensive exercise intervention strategy on modifiable cardiovascular risk factors in subjects with type 2 diabetes mellitus: a randomized controlled trial: the Italian Diabetes and Exercise Study (IDES). Arch Intern Med. 2010 Nov 8. 170(20):1794-803. [QxMD MEDLINE Link].
Church TS, Blair SN, Cocreham S, Johannsen N, Johnson W, Kramer K, et al. Effects of aerobic and resistance training on hemoglobin A1c levels in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2010 Nov 24. 304(20):2253-62. [QxMD MEDLINE Link]. [Full Text].
Chudyk A, Petrella RJ. Effects of exercise on cardiovascular risk factors in type 2 diabetes: a meta-analysis. Diabetes Care. 2011 May. 34(5):1228-37. [QxMD MEDLINE Link]. [Full Text].
Loimaala A, Groundstroem K, Rinne M, Nenonen A, Huhtala H, Parkkari J, et al. Effect of long-term endurance and strength training on metabolic control and arterial elasticity in patients with type 2 diabetes mellitus. Am J Cardiol. 2009 Apr 1. 103(7):972-7. [QxMD MEDLINE Link].
Hegde SV, Adhikari P, Kotian S, Pinto VJ, D'Souza S, D'Souza V. Effect of 3-month yoga on oxidative stress in type 2 diabetes with or without complications: a controlled clinical trial. Diabetes Care. 2011 Oct. 34(10):2208-10. [QxMD MEDLINE Link]. [Full Text].
Dixon JB, Zimmet P, Alberti KG, Rubino F. Bariatric surgery: an IDF statement for obese Type 2 diabetes. Diabet Med. 2011 Jun. 28(6):628-42. [QxMD MEDLINE Link]. [Full Text].
Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002 Feb 7. 346(6):393-403. [QxMD MEDLINE Link]. [Full Text].
Davenport L. 'Historic' Guidelines on Role of Bariatric Surgery in Diabetes. Medscape Medical News. May 25, 2016. [Full Text].
Rubino F, Nathan DM, Eckel RH, et al. Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations. Diabetes Care. 2016 Jun. 39 (6):861-77. [QxMD MEDLINE Link]. [Full Text].
Kashyap SR, Bhatt DL, Wolski K, Watanabe RM, Abdul-Ghani M, Abood B, et al. Metabolic Effects of Bariatric Surgery in Patients With Moderate Obesity and Type 2 Diabetes: Analysis of a randomized control trial comparing surgery with intensive medical treatment. Diabetes Care. 2013 Feb 25. [QxMD MEDLINE Link].
Tucker ME. Bariatric Surgery: Many Can Come Off Insulin Long Term. Medscape. 2017 Nov 6. [Full Text].
Cigolle CT, Lee PG, Langa KM, Lee YY, Tian Z, Blaum CS. Geriatric conditions develop in middle-aged adults with diabetes. J Gen Intern Med. 2011 Mar. 26(3):272-9. [QxMD MEDLINE Link]. [Full Text].
Schernhammer E, Hansen J, Rugbjerg K, Wermuth L, Ritz B. Diabetes and the risk of developing Parkinson's disease in Denmark. Diabetes Care. 2011 May. 34(5):1102-8. [QxMD MEDLINE Link]. [Full Text].
Cereda E, Barichella M, Pedrolli C, Klersy C, Cassani E, Caccialanza R, et al. Diabetes and risk of Parkinson's disease: a systematic review and meta-analysis. Diabetes Care. 2011 Dec. 34(12):2614-23. [QxMD MEDLINE Link]. [Full Text].
Chen HF, Chen P, Li CY. Risk of malignant neoplasm of the pancreas in relation to diabetes: a population-based study in Taiwan. Diabetes Care. 2011 May. 34(5):1177-9. [QxMD MEDLINE Link]. [Full Text].
Kanaya AM, Adler N, Moffet HH, Liu J, Schillinger D, Adams A, et al. Heterogeneity of diabetes outcomes among asians and pacific islanders in the US: the diabetes study of northern california (DISTANCE). Diabetes Care. 2011 Apr. 34(4):930-7. [QxMD MEDLINE Link]. [Full Text].
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998 Sep 12. 317(7160):703-13. [QxMD MEDLINE Link]. [Full Text].
Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998 Jun 13. 351(9118):1755-62. [QxMD MEDLINE Link].
[Guideline] Doyle-Delgado K, Chamberlain JJ, Shubrook JH, Skolnik N, Trujillo J. Pharmacologic Approaches to Glycemic Treatment of Type 2 Diabetes: Synopsis of the 2020 American Diabetes Association's Standards of Medical Care in Diabetes Clinical Guideline. Ann Intern Med. 2020 Sep 1. [QxMD MEDLINE Link]. [Full Text].
[Guideline] ElSayed NA, Aleppo G, Aroda VR, et al. Introduction and Methodology: Standards of Care in Diabetes-2023. Diabetes Care. 2023 Jan 1. 46 (Supplement_1):S1-S4. [QxMD MEDLINE Link]. [Full Text].
Tucker ME. ADA Advises New BP, Lipid Targets for People With Diabetes. Medscape Medical News. 2022 Dec 13. [Full Text].
Anderson RJ, Bahn GD, Moritz TE, Kaufman D, Abraira C, Duckworth W. Blood pressure and cardiovascular disease risk in the Veterans Affairs Diabetes Trial. Diabetes Care. 2011 Jan. 34(1):34-8. [QxMD MEDLINE Link]. [Full Text].
[Guideline] de Boer IH, Bangalore S, Benetos A, et al. Diabetes and Hypertension: A Position Statement by the American Diabetes Association. Diabetes Care. 2017 Sep. 40 (9):1273-84. [QxMD MEDLINE Link]. [Full Text].
[Guideline] Jenkins K. ADA Updates Recommendations for Managing Hypertension in Diabetes. Medscape. 4 Sep 2017. [Full Text].
FDA Drug Safety Communication: FDA review of cardiovascular risks for diabetics taking hypertension drug olmesartan not conclusive; label updates required. US Food and Drug Administration. Available at http://www.fda.gov/Drugs/DrugSafety/ucm402323.htm. Accessed: June 29, 2014.
O'Riordan M. No CV risk with olmesartan in diabetics, says FDA review. Medscape Medical News. June 24, 2014. [Full Text].
Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, et al. Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes. N Engl J Med. 2012 Nov 3. [QxMD MEDLINE Link].
Hermida RC, Ayala DE, Mojon A, Fernandez JR. Influence of time of day of blood pressure-lowering treatment on cardiovascular risk in hypertensive patients with type 2 diabetes. Diabetes Care. 2011 Jun. 34(6):1270-6. [QxMD MEDLINE Link]. [Full Text].
Management of dyslipidemia in adults with diabetes. Diabetes Care. 2000 Jan. 23 Suppl 1:S57-60. [QxMD MEDLINE Link].
Bell DS, Bakris GL, McGill JB. Comparison of carvedilol and metoprolol on serum lipid concentration in diabetic hypertensive patients. Diabetes Obes Metab. 2009 Mar. 11(3):234-8. [QxMD MEDLINE Link].
Aspirin therapy in diabetes. Diabetes Care. 2000 Jan. 23 Suppl 1:S61-2. [QxMD MEDLINE Link].
Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008 Nov 12. 300(18):2134-41. [QxMD MEDLINE Link].
Saito Y, Morimoto T, Ogawa H, Nakayama M, Uemura S, Doi N, et al. Low-dose aspirin therapy in patients with type 2 diabetes and reduced glomerular filtration rate: subanalysis from the JPAD trial. Diabetes Care. 2011 Feb. 34(2):280-5. [QxMD MEDLINE Link]. [Full Text].
Okada S, Morimoto T, Ogawa H, Kanauchi M, Nakayama M, Uemura S, et al. Differential effect of low-dose aspirin for primary prevention of atherosclerotic events in diabetes management: a subanalysis of the JPAD trial. Diabetes Care. 2011 Jun. 34(6):1277-83. [QxMD MEDLINE Link]. [Full Text].
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994 Nov 19. 344(8934):1383-9. [QxMD MEDLINE Link].
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002 Jul 6. 360(9326):7-22. [QxMD MEDLINE Link].
Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003 Apr 5. 361(9364):1149-58. [QxMD MEDLINE Link].
Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004 Aug 21-27. 364(9435):685-96. [QxMD MEDLINE Link].
Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011 Jun 22. 305(24):2556-64. [QxMD MEDLINE Link].
Tucker ME. Statins Up Type 2 Diabetes Risk, Overweight at Greatest Risk. Medscape Medical News. 2019 Mar 13. [Full Text].
Ahmadizar F, OchoaRosales C, Glisic M, Franco OH, Muka T, Stricker BH. Associations of statin use with glycaemic traits and incident type 2 diabetes. Br J Clin Pharmacol. 2019 Mar 5. [QxMD MEDLINE Link]. [Full Text].
Tucker ME. ADA endorses ACC/AHA statin guidelines, with caveats. Medscape Medical News. Available at http://www.medscape.com/viewarticle/837138. Accessed: December 24, 2014.
Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999 Aug 5. 341(6):410-8. [QxMD MEDLINE Link].
Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, MacGregor JM, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009 Jun 11. 360(24):2503-15. [QxMD MEDLINE Link]. [Full Text].
Agardh E, Tababat-Khani P. Adopting 3-year screening intervals for sight-threatening retinal vascular lesions in type 2 diabetic subjects without retinopathy. Diabetes Care. 2011 Jun. 34(6):1318-9. [QxMD MEDLINE Link]. [Full Text].
Sjolie AK, Klein R, Porta M, Orchard T, Fuller J, Parving HH, et al. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet. 2008 Oct 18. 372(9647):1385-93. [QxMD MEDLINE Link].
Oshitari T, Asaumi N, Watanabe M, Kumagai K, Mitamura Y. Severe macular edema induced by pioglitazone in a patient with diabetic retinopathy: a case study. Vasc Health Risk Manag. 2008. 4(5):1137-40. [QxMD MEDLINE Link]. [Full Text].
Food and Drug Administration. FDA Requires Boxed Warning and Risk Mitigation Strategy for Metoclopramide-Containing Drugs. U.S. Food and Drug Administration. Available at http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm149533.htm. Accessed: August 4, 2010.
Chou KL, Galetta SL, Liu GT, Volpe NJ, Bennett JL, Asbury AK, et al. Acute ocular motor mononeuropathies: prospective study of the roles of neuroimaging and clinical assessment. J Neurol Sci. 2004 Apr 15. 219(1-2):35-9. [QxMD MEDLINE Link].
Queale WS, Seidler AJ, Brancati FL. Glycemic control and sliding scale insulin use in medical inpatients with diabetes mellitus. Arch Intern Med. 1997 Mar 10. 157(5):545-52. [QxMD MEDLINE Link].
Sawin CT. Action without benefit. The sliding scale of insulin use. Arch Intern Med. 1997 Mar 10. 157(5):489. [QxMD MEDLINE Link].
Wiener RS, Wiener DC, Larson RJ. Benefits and risks of tight glucose control in critically ill adults: a meta-analysis. JAMA. 2008 Aug 27. 300(8):933-44. [QxMD MEDLINE Link].
Finfer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009 Mar 26. 360(13):1283-97. [QxMD MEDLINE Link].
Van den Berghe G, Wilmer A, Milants I, Wouters PJ, Bouckaert B, Bruyninckx F, et al. Intensive insulin therapy in mixed medical/surgical intensive care units: benefit versus harm. Diabetes. 2006 Nov. 55(11):3151-9. [QxMD MEDLINE Link].
Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ. 1997 May 24. 314(7093):1512-5. [QxMD MEDLINE Link]. [Full Text].
Malmberg K, Ryden L, Wedel H, Birkeland K, Bootsma A, Dickstein K, et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J. 2005 Apr. 26(7):650-61. [QxMD MEDLINE Link].
Mellbin LG, Malmberg K, Norhammar A, Wedel H, Ryden L. Prognostic implications of glucose-lowering treatment in patients with acute myocardial infarction and diabetes: experiences from an extended follow-up of the Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) 2 Study. Diabetologia. 2011 Jun. 54(6):1308-17. [QxMD MEDLINE Link].
Avanzini F, Marelli G, Donzelli W, Busi G, Carbone S, Bellato L, et al. Transition from intravenous to subcutaneous insulin: effectiveness and safety of a standardized protocol and predictors of outcome in patients with acute coronary syndrome. Diabetes Care. 2011 Jul. 34(7):1445-50. [QxMD MEDLINE Link]. [Full Text].
Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002 Feb 7. 346(6):393-403. [QxMD MEDLINE Link]. [Full Text].
Vanderwood KK, Hall TO, Harwell TS, Butcher MK, Helgerson SD. Implementing a state-based cardiovascular disease and diabetes prevention program. Diabetes Care. 2010 Dec. 33(12):2543-5. [QxMD MEDLINE Link]. [Full Text].
Reis JP, Loria CM, Sorlie PD, Park Y, Hollenbeck A, Schatzkin A. Lifestyle factors and risk for new-onset diabetes: a population-based cohort study. Ann Intern Med. 2011 Sep 6. 155(5):292-9. [QxMD MEDLINE Link].
Yeh HC, Duncan BB, Schmidt MI, Wang NY, Brancati FL. Smoking, smoking cessation, and risk for type 2 diabetes mellitus: a cohort study. Ann Intern Med. 2010 Jan 5. 152(1):10-7. [QxMD MEDLINE Link].
Dong JY, Xun P, He K, Qin LQ. Magnesium intake and risk of type 2 diabetes: meta-analysis of prospective cohort studies. Diabetes Care. 2011 Sep. 34(9):2116-22. [QxMD MEDLINE Link]. [Full Text].
Ibarrola-Jurado N, Salas-Salvado J, Martinez-Gonzalez MA, Bullo M. Dietary phylloquinone intake and risk of type 2 diabetes in elderly subjects at high risk of cardiovascular disease. Am J Clin Nutr. 2012 Nov. 96(5):1113-8. [QxMD MEDLINE Link].
National Diabetes Information Clearinghouse. Insulin Resistance and Pre-diabetes. Available at http://diabetes.niddk.nih.gov/dm/pubs/insulinresistance/#medicines.
Xiang AH, Hodis HN, Kawakubo M, Peters RK, Kjos SL, Marroquin A, et al. Effect of pioglitazone on progression of subclinical atherosclerosis in non-diabetic premenopausal Hispanic women with prior gestational diabetes. Atherosclerosis. 2008 Jul. 199(1):207-14. [QxMD MEDLINE Link]. [Full Text].
Bosch J, Yusuf S, Gerstein HC, Pogue J, Sheridan P, Dagenais G, et al. Effect of ramipril on the incidence of diabetes. N Engl J Med. 2006 Oct 12. 355(15):1551-62. [QxMD MEDLINE Link].
Chiasson JL. Acarbose for the prevention of diabetes, hypertension, and cardiovascular disease in subjects with impaired glucose tolerance: the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) Trial. Endocr Pract. 2006 Jan-Feb. 12 Suppl 1:25-30. [QxMD MEDLINE Link].
[Guideline] Jenkins K. ADA Updates Recommendations for Managing Hypertension in Diabetes. Medscape. 2017 Sep 4. [Full Text].
[Guideline] de Boer IH, Bangalore S, Benetos A, et al. Diabetes and Hypertension: A Position Statement by the American Diabetes Association. Diabetes Care. 2017 Sep. 40 (9):1273-1284. [QxMD MEDLINE Link]. [Full Text].
[Guideline] Davenport L. ADA Releases Comprehensive Type 2 Diabetes Guidelines for Youth. Medscape Medical News. 2018 Nov 19. [Full Text].
[Guideline] Davies MJ, D'Alessio DA, Fradkin J, et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018 Oct 4. [QxMD MEDLINE Link]. [Full Text].
[Guideline] Ivers NM, Jiang M, Alloo J, et al. Diabetes Canada 2018 clinical practice guidelines: Key messages for family physicians caring for patients living with type 2 diabetes. Can Fam Physician. 2019 Jan. 65 (1):14-24. [QxMD MEDLINE Link]. [Full Text].
[Guideline] LeRoith D, Biessels GJ, Braithwaite SS, et al. Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline. J Clin Endocrinol Metab. 2019 May 1. 104 (5):1520-74. [QxMD MEDLINE Link]. [Full Text].
[Guideline] Tucker ME. New Endocrine Society Guidelines Address Diabetes in Older Adults. Medscape Medical News. 2019 Mar 23. [Full Text].
[Guideline] Busko M. ESC Diabetes and CVD Guideline: 'Unprecedented' New Evidence. Medscape Medical News. 2019 Sep 2. [Full Text].
[Guideline] Tucker ME. More Guidance on 'Vulnerable Subgroup' With Diabetes and COVID-19. Medscape Medical News. 2020 Apr 28. [Full Text].
[Guideline] Bornstein SR, Rubino F, Khunti K, et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. 2020 Apr 23. [QxMD MEDLINE Link]. [Full Text].
[Guideline] Grunberger G, Sherr J, Allende M, et al. American Association of Clinical Endocrinology Clinical Practice Guideline: The Use of Advanced Technology in the Management of Persons With Diabetes Mellitus. Endocr Pract. 27 (2021):505-37. [Full Text].
Tucker ME. 'A Better Picture': First AACE Guidelines on Diabetes Technology. Medscape Medical News. 2021 May 31. [Full Text].
[Guideline] Mannucci E, Candido R, Monache LD, et al. Italian guidelines for the treatment of type 2 diabetes. Acta Diabetol. 2022 May. 59 (5):579-622. [QxMD MEDLINE Link]. [Full Text].
[Guideline] American Diabetes Association. 1. Improving Care and Promoting Health in Populations: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018 Jan. 41 (Suppl 1):S7-S12. [QxMD MEDLINE Link]. [Full Text].
[Guideline] American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018 Jan. 41 (Suppl 1):S13-S27. [QxMD MEDLINE Link]. [Full Text].
[Guideline] American Diabetes Association. 3. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018 Jan. 41 (Suppl 1):S28-S37. [QxMD MEDLINE Link]. [Full Text].
[Guideline] American Diabetes Association. 4. Lifestyle Management: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018 Jan. 41 (Suppl 1):S38-S50. [QxMD MEDLINE Link]. [Full Text].
[Guideline] American Diabetes Association. 5. Prevention or Delay of Type 2 Diabetes: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018 Jan. 41 (Suppl 1):S51-4. [QxMD MEDLINE Link]. [Full Text].
[Guideline] American Diabetes Association. 6. Glycemic Targets: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018 Jan. 41 (Suppl 1):S55-S64. [QxMD MEDLINE Link]. [Full Text].
[Guideline] American Diabetes Association. 7. Obesity Management for the Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018 Jan. 41 (Suppl 1):S65-S72. [QxMD MEDLINE Link]. [Full Text].
[Guideline] American Diabetes Association. 8. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018 Jan. 41 (Suppl 1):S73-S85. [QxMD MEDLINE Link]. [Full Text].
[Guideline] American Diabetes Association. 9. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018 Jan. 41 (Suppl 1):S86-S104. [QxMD MEDLINE Link]. [Full Text].
[Guideline] American Diabetes Association. 10. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018 Jan. 41 (Suppl 1):S105-18. [QxMD MEDLINE Link]. [Full Text].
[Guideline] American Diabetes Association. 11. Older Adults: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018 Jan. 41 (Suppl 1):S119-25. [QxMD MEDLINE Link]. [Full Text].
[Guideline] American Diabetes Association. 12. Children and Adolescents: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018 Jan. 41 (Suppl 1):S126-36. [QxMD MEDLINE Link]. [Full Text].
[Guideline] American Diabetes Association. 13. Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018 Jan. 41 (Suppl 1):S137-43. [QxMD MEDLINE Link]. [Full Text].
[Guideline] American Diabetes Association. 14. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018 Jan. 41 (Suppl 1):S144-51. [QxMD MEDLINE Link]. [Full Text].
[Guideline] American Diabetes Association. 15. Diabetes Advocacy: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018 Jan. 41 (Suppl 1):S152-3. [QxMD MEDLINE Link]. [Full Text].
[Guideline] Summary of Revisions: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018 Jan. 41 (Suppl 1):S4-S6. [QxMD MEDLINE Link]. [Full Text].
[Guideline] Tucker ME. ADA 2018 Standards Address Diabetes Drugs With CV Benefit. Medscape. 2017 Dec 8. [Full Text].
One adult in ten will have diabetes by 2030. International Diabetes Federation. November 14, 2011. Available at http://www.idf.org/media-events/press-releases/2011/diabetes-atlas-5th-edition.
Tucker M. FDA Approves Inhaled Insulin Afrezza for Diabetes. Medscape Medical News. Available at http://www.medscape.com/viewarticle/827539. Accessed: July 5, 2014.
Tucker M. FDA OKs Xigduo XR, a New Dapagliflozin-Metformin Combo. Medscape Medical News. Available at http://www.medscape.com/viewarticle/834133. Accessed: November 10, 2014.
[Guideline] Tucker ME. USPSTF: screen everyone 45 and older for abnormal glucose. Medscape Medical News. Oct 6 2014. [Full Text].
[Guideline] USPSTF. Public comment on draft recommendation statement and draft evidence review: screening for abnormal glucose and type 2 diabetes mellitus. US Preventive Services Task Force. Available at http://www.uspreventiveservicestaskforce.org/Announcements/News/Item/public-comment-on-draft-recommendation-statement-and-draft-evidence-review-screening-for-abnormal-glucose-and-type-2-diabetes-mellitus. Accessed: Oct 14 2014.

Media Gallery

Simplified scheme for the pathophysiology of type 2 diabetes mellitus.
Prevalence of type 2 diabetes mellitus in various racial and ethnic groups in the United States (2007-2009 data).
Prevalence of diabetes mellitus type 2 by age in the United States (2007 estimates).
Possible physical examination findings in patients with type 2 diabetes mellitus.
Diagnostic criteria (American Diabetes Association) for diabetes mellitus type 2.
Major findings from the primary glucose study in the United Kingdom Prospective Diabetes Study (UKPDS).
Results from metformin substudy in the United Kingdom Prospective Diabetes Study (UKPDS).
Findings from the blood pressure substudy in the United Kingdom Prospective Diabetes Study (UKPDS).
Laboratory monitoring guidelines for patients with type 2 diabetes mellitus.
American Diabetes Association guidelines for low-density lipoprotein cholesterol in diabetes mellitus type 2.
Treatment of type 2 diabetes mellitus.
Types of insulin. Premixed insulins can be assumed to have a combination of the onset, peak, and duration of the individual components.
Simplified scheme for using insulin in treating patients with type 2 diabetes mellitus.
Simplified scheme of idealized blood glucose values and multiple dose insulin therapy in type 2 diabetes mellitus.

of 14

Author

Romesh Khardori, MD, PhD, FACP (Retired) Professor, Division of Endocrinology, Diabetes and Metabolism, Department of Internal Medicine, Eastern Virginia Medical School

Romesh Khardori, MD, PhD, FACP is a member of the following medical societies: American Association of Clinical Endocrinologists, American College of Physicians, American Diabetes Association, Endocrine Society

Disclosure: Nothing to disclose.

Chief Editor

George T Griffing, MD Professor Emeritus of Medicine, St Louis University School of Medicine

George T Griffing, MD is a member of the following medical societies: American Association for Physician Leadership, American Association for the Advancement of Science, American College of Medical Practice Executives, American College of Physicians, American Diabetes Association, American Federation for Medical Research, American Heart Association, Central Society for Clinical and Translational Research, Endocrine Society, International Society for Clinical Densitometry, Southern Society for Clinical Investigation

Disclosure: Nothing to disclose.

Acknowledgements

Howard A Bessen, MD Professor of Medicine, Department of Emergency Medicine, University of California, Los Angeles, David Geffen School of Medicine; Program Director, Harbor-UCLA Medical Center

Howard A Bessen, MD is a member of the following medical societies: American College of Emergency Physicians